美欧融资 biotech板块首页
总表:从这里开始
2025 年起有新融资的美欧 biotech 总表
NewCo 与回报
2025 年起的 NewCo:56 家现状,以及谁真正赚了钱NewCo 上市前后:定价、暴涨、回落与现状NewCo 手上的资产走到哪一步:临床阶段与上市情况中国资产 NewCo 的交易结构
wet-lab 模式
262 家怎么做湿实验:自建、混合还是虚拟?

2025 年起有新融资的美欧 biotech 总表:262 家

整理 2026-11-05 · 来源与可靠度标注见正文
本文目录
  1. 口径
  2. 汇总
  3. 总表(美国在前,按累计披露金额降序)

更新:2026-11-05。本表是本板块的入口:每家公司一行,字段覆盖地点、模态、融资、投资人、状态、wet-lab 模式、中国提供方、是否 NewCo、是否 AI 公司、官方 X 账号。详细分类分析和 70 家逐家证据见本板块下一篇。

配套页面:Startup X map — US/EU biotech 2025–26。它基于同一份公司清单核对了每家的官方 X(Twitter)账号:74 / 263 家有可信的公司账号(28%),美国 57/202、欧洲 17/61;按匹配置信度高 47、中 22、低 5。有 X 账号的公司里自建 39%、混合 35%、虚拟 14%,远高于全样本的虚拟比例,因为 NewCo 和隐身期公司大多不开官方账号。粉丝数最高的是 Isomorphic Labs(66k)、NewLimit(43k)、Life Biosciences(24k)、Chai Discovery(7.1k)、Lila Sciences(4.5k)。本表最后两列即来自该页。

口径

  • 样本:2025-01 起有新融资的美国和欧洲 biotech,来源为 BioPharma Dive 融资追踪(26 家头部 VC 的组合,任意金额,截至 2026-10-30)加 Fierce Biotech Fundraising Tracker($50M 以上,截至 2026-09-30)。两源按日期 ±14 天和金额去重。
  • 缺口:$50M 以下且非 26 家 VC 投的轮次基本缺失,欧洲小轮缺得最多;2026 年 10 月只有 BioPharma Dive 部分。
  • wet-lab 模式:自建 = 发现阶段湿实验主要在自有实验室;混合 = 自有实验室加明确命名的外包环节;虚拟 = 发现阶段没有自有实验室(外包给 CRO、授权方或学术实验室)。括号内 H/M/L 为置信度。
  • NewCo:围绕授权引进或收购资产建立、没有自有发现管线的公司。AI 公司:公开描述以 AI / 计算驱动为核心。
  • 中国提供方:是 = 有命名的中国 CRO/CDMO 或授权方;? = 未找到信息。
  • X 账号:只收公司官方账号,不收创始人账号;粉丝数为 2026-11 初快照。

汇总

家数 自建 混合 虚拟 不明 NewCo AI 公司 中国提供方=是 有 X 账号
全部 262 89 66 105 2 51 48 48 74
美国 201 70 51 78 2 41 38 39 57
欧洲 61 19 15 27 0 10 10 9 17
融资时阶段 家数 自建 混合 虚拟 有 X 账号
Preclinical 90 44 19 25 19
Phase 1 69 21 19 29 16
— 53 17 16 20 16
Phase 2 37 4 8 25 15
Phase 3 8 3 1 4 5
Marketed 2 0 0 2 2
Undisclosed 2 0 2 0 1
Phase 0 1 0 1 0 0
模态 家数 自建 混合 虚拟 有 X 账号
Small molecules 73 19 9 44 14
Biologics 70 26 16 27 17
— 53 17 16 20 16
Cell or gene therapy 32 17 11 4 13
Nucleic acids 11 4 4 3 4
Multiple 6 0 3 3 4
Undisclosed 5 3 1 1 0
Drug discovery 4 1 2 1 3

总表(美国在前,按累计披露金额降序)

# 公司 地区 国家 / 城市 模态 疾病领域 融资时阶段 轮次 最新一轮 累计 $M 投资人(点开看全部) 状态 wet-lab 中国提供方 NewCo AI X 账号 粉丝
1 Chai Discovery 美国 USA / San Francisco CA Drug discovery Undisclosed Undisclosed
3 轮2025-08-06 Series A $70M
2025-12-15 Series B $130M
2026-07-14 Series C $400M
2026-07-14 Series C $400M 600
Menlo VenturesMenlo Ventures, with new investors Yosemite, DST Global Partners, SV Angel, Avenir, DCVC and others, and existing investors Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, Fred Ehrsam and others / Oak HC/FT, General Catalyst, Thrive Capital, OpenAI, Dimension, Menlo Ventures, Lachy Groom, Yosemite, Neo, SV Angel, Emerson Collective and Glade Brook / Index Ventures / Bain Capital Life Sciences
私有 混合(M) ? ✓ @chaidiscovery 7.1k
2 Kailera Therapeutics 美国 USA / Waltham, MA Multiple Metabolic diseases Phase 2 1 轮 2025-10-14 Series B $600M 600
Bain Capital Private EquityBain Capital Life Sciences / Bain Capital Life Sciences, Atlas Venture / Bain Capital Private Equity, Adage Capital Management, Canada Pension Plan Investment Board, Invus, Janus Henderson Investors, Perseverance Capital, Qatar Investment Authority, Royalty Pharma, Citadel's Surveyor Capital, accounts advised by T. Rowe Price Associates, Atlas Venture, Bain Capital Life Sciences, RTW Investments, Si
上市 虚拟(H) 是 ✓ @kaileratx 117
3 NewLimit 美国 US / South San Francisco Cell or gene therapy Other Preclinical
2 轮2025-05-06 Series B $130M
2026-06-02 Series C $435M
2026-06-02 Series C $435M 565
Founders FundKleiner Perkins, Nat Friedman/Daniel Gross, Khosla Ventures, Human Capital, Valor Equity Partners, Dimension, Founders Fund and Brian Armstrong / Founders Fund, Thrive Capital, Greenoaks, Quiet Capital / Eli Lilly and Company / Founders Fund, Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Nat Friedman/Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital and ot
私有 自建(H) ? ✓ @newlimit 43k
4 Kardigan 美国 USA / South San Francisco, CA Undisclosed Other Undisclosed
2 轮2025-01-10 Series A $300M
2025-10-14 Series B $254M
2025-10-14 Series B $254M 554
Fidelity Management & Research CompanyPerceptive Advisors, Arch Venture Partners, Sequoia Heritage / Arch Venture Partners / Perceptive Advisors, ARCH Venture Partners and Sequoia Heritage / Fidelity Management & Research Company, accounts advised by T. Rowe Price Investment Management, ARCH Venture Partners and Sequoia Heritage
上市 混合(M) ? — —
5 Lila Sciences 美国 US / Cambridge MA — — —
3 轮2025-03-10 Seed $200M
2025-09-15 Series A $235M
2025-10-14 A extension $115M
2025-10-14 A extension $115M 550
Flagship PioneeringFlagship Pioneering, General Catalyst, March Capital, ARK Venture Fund, Altitude Life Science Ventures, Blue Horizon Advisors, State of Michigan Retirement System, Modi Ventures and a wholly owned subsidiary of the Abu Dhabi Investment Authority / Braidwell, Collective Global, Altitude Life Science Ventures, Alumni Ventures, ARK Venture Fund, Common Metal, Flagship Pioneering, General Catalyst, Ma
私有 自建(H) 否 ✓ @LilaSciences 4.5k
6 Ollin Biosciences 美国 US / South San Francisco Biologics Eye diseases Phase 1
2 轮2025-09-17 Series A $100M
2026-06-24 Series B $330M
2026-06-24 Series B $330M 430
TCGXArch Venture Partners, Mubadala Capital, Monograph Capital / Arch Venture Partners / ARCH Venture Partners, Mubadala Capital and Monograph Capital / TCGX, ARCH Venture Partners, a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board (CPP Investments), RA Capital Management, accounts advised by T. Rowe Price Investment Management, Inc., a leading so
私有 虚拟(H) 是 ✓ @OllinBio 30
7 Beeline Medicines 美国 USA / Boston, MA Multiple Immune diseases Phase 2
2 轮2026-04-15 Series A $300M
2026-06-30 Series A $126M
2026-06-30 Series A $126M 426
Bain Capital Life SciencesBain Capital / Bain Capital Life Sciences / Bain Capital and others
私有 虚拟(H) ? ✓ @BeelineMed 0
8 Dispatch Bio 美国 USA / Philadelphia, PA Cell or gene therapy Cancer Preclinical 1 轮 2025-07-23 Series A $201M 417
Arch Venture PartnersArch Venture Partners, Parker Institute for Cancer Immunotherapy / Arch Venture Partners, Alexandria Venture Investments / Arch Venture Partners, Parker Institute for Cancer Immunotherapy, Bristol Myers Squibb, the University of Pennsylvania, Stanford University and Alexandria Venture Investments
私有 混合(H) 否 @DispatchBio 81
9 MapLight Therapeutics 美国 US / Redwood City Small molecules CNS disorders Phase 2 1 轮 2025-07-28 Series D $373M 373
Forbion and Life Sciences at Goldman SacForbion, Goldman Sachs Alternatives / Forbion, Novo Holdings / Forbion and Life Sciences at Goldman Sachs Alternatives, with participation from additional new investors Sanofi, accounts advised by T. Rowe Price Investment Management and Avego BioScience Capital, and existing investors including funds managed by Novo Holdings, 5AM Ventures, Blue Owl Healthcare Opportunities and others
上市 混合(H) ? @Maplightrx 242
10 Eikon Therapeutics 美国 USA / Millbrae, CA Multiple Multiple Phase 3 1 轮 2025-02-26 Series D $351M 351
Lux CapitalAlexandria Venture Investments / Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, funds and accounts advised by T. Rowe Price Associates, and UC Investments (Office of the Chief Investment Officer of the Regents of the University of California), among others
上市 混合(H) ? @EikonTX 954
11 Dren Bio 美国 USA / San Mateo, CA Biologics Cancer Phase 3 1 轮 2026-10-29 Series C $350M 350
Juvia GroupJuvia Group, Lightspeed Venture Partners / OrbiMed
私有 自建(M) ? @DrenBio 5
12 Abcuro 美国 USA / Newton MA Biologics Multiple Phase 3
2 轮2025-02-12 Series C $200M
2026-08-18 Series D $77M
2026-08-18 Series D $77M 343
New Enterprise AssociatesNEA / NEA, RA Capital Management, Bain Capital Life Sciences, Samsara BioCapital, Sanofi Ventures / New Enterprise Associates, Foresite Capital, RA Capital Management, Bain Capital Life Sciences, Redmile Group, Samsara BioCapital, Sanofi Ventures, Pontifax, Mass General Brigham Ventures, New Leaf Ventures, funds managed by abrdn, funds and accounts managed by BlackRock, Eurofarma Ventures and Soleus
私有 虚拟(M) 否 @abcuro 16
13 Soufflé Therapeutics 美国 US / Watertown MA Nucleic acids Rare diseases Preclinical
2 轮2025-10-07 Series A $200M
2026-10-13 Series B $135M
2026-10-13 Series B $135M 335
Polaris PartnersPolaris Partners, Arch Venture Partners, Novo Holdings / Juvia Group / Arch Venture Partners, Polaris Partners
私有 自建(M) ? — —
14 Crystalys Therapeutics 美国 USA / San Diego, CA Small molecules Immune diseases Marketed
2 轮2025-09-30 Series A $205M
2026-07-22 Series C $130M
2026-07-22 Series C $130M 335
Frazier Life SciencesNovo Holdings, SR One, Catalys Pacific / Alexandria Venture Investments, Novo Holdings / Novo Holdings, Catalys Pacific, SR One, Lightstone VC, Longwood Fund, Alexandria Venture Investments and others / Frazier Life Sciences / Novo Holdings, Alexandria Venture Investments / Frazier Life Sciences, Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge
私有 虚拟(M) ? ✓ @Crystalys_Tx 11
15 Expedition Medicines 美国 USA / San Francisco Bay Area, CA Small molecules Other Phase 2
3 轮2025-10-09 Series A $165M
2025-10-22 未披露轮 $50M
2026-08-05 Series B $115M
2026-08-05 Series B $115M 330
Sofinnova InvestmentsSofinnova Investments, Novo Holdings / Forbion, Sofinnova Investments, Sanofi Ventures, Novo Holdings / Sofinnova Investments, Novo Holdings, Forbion, KKR's Dawn Biopharma, Adage, Balyasny, Logos Capital, Sanofi Ventures, BVF Partners and Venrock Healthcare Capital Partners / Flagship Pioneering / General Atlantic / RA Capital Management, Vivo Capital, Novo Holdings, Forbion, Sofinnova Investments, Sa
私有 虚拟(M) 是 ✓ — —
16 Star Therapeutics 美国 US / South San Francisco Biologics Rare diseases Phase 3
2 轮2025-09-30 Series D $125M
2026-10-23 未披露轮 $200M
2026-10-23 未披露轮 $200M 325
Sanofi VenturesSanofi Ventures, Viking Global Investors / OrbiMed, Sofinnova Investments, RA Capital Management, Sanofi Ventures / Sanofi Ventures, Viking Global Investors, Sofinnova, Blue Owl Capital, RA Capital Management, Janus Henderson Investors, Fraizer Life Sciences, GordonMD Global Investments and others / OrbiMed, Janus Henderson Investors / OrbiMed, RA Capital Management, Sofinnova Investments
私有 自建(M) ? @STAR_Biotech 41
17 Korsana Biosciences 美国 USA / Boston, MA Biologics CNS disorders Preclinical
2 轮2025-09-01 Series A $150M
2026-02-18 Seed / A $175M
2026-02-18 Seed / A $175M 325
FairmountWellington Management, TCGX / Sanofi Ventures / Fairmount, Venrock Healthcare Capital Partners, Wellington Management, TCGX, J.P. Morgan Life Sciences Private Capital, Janus Henderson Investors, Sanofi Ventures, Foresite Capital and others
反向并购 虚拟(H) 是 ✓ — —
18 Kriya Therapeutics 美国 USA / Redwood City, CA — — — 1 轮 2025-08-18 Series N/A $313M 313 N/A 私有 自建(H) 否 @kriyatx 280
19 Enveda 美国 USA / Boulder, CO — — — 1 轮 2026-09-23 Series E $311M 311
Catalio Capital ManagementCatalio Capital Management, Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital (a Citadel company), Digitalis Ventures, a notable Sovereign Wealth Fund, and Alderline Group, Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital and Lux Capital
私有 自建(H) ? ✓ @enveda 2.7k
20 Parabilis Medicines 美国 US / Boston Biologics Cancer Phase 1 1 轮 2026-01-08 Series F $305M 305
RA Capital ManagementRA Capital Management, Fidelity Management & Research, Janus Henderson Investors / RA Capital Management, venBio, Arch Venture Partners, GV / RA Capital Management, Fidelity Management & Research Company, Janus Henderson Investors, Frazier Life Sciences, Soleus Capital, a life science-dedicated investment fund, venBio Partners, Cormorant Asset Management, Nextech Invest, ARCH Venture Partners, Milky
上市 混合(H) 是 ✓ @FogPharma 43
21 Encoded Therapeutics 美国 USA / South San Francisco, CA Cell or gene therapy CNS disorders Phase 1 1 轮 2026-09-09 Series F $275M 275
Google VenturesGV / GV, Arch Venture Partners, / Google Ventures, another healthcare fund, ARCH Venture Partners, Braidwell LP, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund 2 and Venrock
私有 自建(H) ? @EncodedTx 320
22 Atrium Therapeutics 美国 USA / San Diego — — — 1 轮 2026-02-27 Series N/A $270M 270 N/A 上市 混合(M) ? — —
23 Mirador Therapeutics 美国 US / San Diego Drug discovery Immune diseases Preclinical 1 轮 2026-01-12 Series B $250M 250 Arch Venture Partners, OrbiMed 私有 混合(M) ? — —
24 Serapha Bio 美国 US / San Diego — — — 1 轮 2026-06-23 Series A $230M 230
RA Capital ManagementRA Capital Management, RTW Investments, Janus Henderson Investors, Decheng Capital, Vivo Capital, Casdin Capital, LifeSci Venture Partners, Logos Capital, Balyasny Asset Management and Eventide Asset Management
反向并购 虚拟(M) 是 ✓ — —
25 Solstice Oncology 美国 US / Boston Biologics Cancer Phase 1 1 轮 2026-09-09 Series A $225M 225
RA Capital ManagementRA Capital Management / RA Capital Management, Forbion / RA Capital Management, Canaan Partners, Forbion and others
私有 虚拟(M) 是 ✓ — —
26 Odyssey Therapeutics 美国 US / Boston Small molecules Immune diseases Phase 2 1 轮 2025-09-10 Series D $213M 213
Affinity Asset AdvisorsOrbiMed, Alexandria Venture Investments / Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, Wedbush Healthcare Partners and all existing investors
上市 混合(H) 是 ✓ @odysseytx 19
27 Aviceda Therapeutics 美国 USA / Cambridge MA Small molecules Other Phase 2 1 轮 2025-01-07 Series C $208M 208
Omega Funds and TCGXOmega Funds, TCGX / OrbiMed / Co-led by Omega Funds and TCGX, with participation from Enavate Sciences, Jeito Capital, Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, funds managed by abrdn Inc., and Digitalis Ventures
私有 混合(M) ? ✓ — —
28 AirNexis Therapeutics 美国 USA / Palo Alto CA Small molecules Other Phase 2 1 轮 2026-01-09 Series A $200M 200
Frazier Life SciencesFrazier Life Sciences / OrbiMed / Frazier Life Sciences, OrbiMed, Life Sciences at Goldman Sachs Alternatives, SR One, Longitude Capital and Enavate Sciences, among others
私有 虚拟(M) 是 ✓ @AirNexis 0
29 Treeline Biosciences 美国 US / Massachusetts Multiple Cancer Phase 1 1 轮 2025-09-03 Series A $200M 200 Arch Venture Partners, OrbiMed, GV / N/A 反向并购 混合(M) ? @TreelineBio 32
30 Tenvie Therapeutics 美国 US / South San Francisco Small molecules CNS disorders Preclinical 1 轮 2025-01-08 未披露轮 $200M 200
Arch Venture PartnersArch Venture Partners, F-Prime Capital, Mubadala Capital / Arch Venture Partners, F-Prime Capital / Arch Venture Partners, F-Prime Capital and Mubadala Capital with participation from other unnamed investors
私有 虚拟(M) 是 ✓ ✓ — —
31 Soley Therapeutics 美国 US / South San Francisco — — — 1 轮 2026-01-07 Series C $200M 200
Surveyor CapitalSurveyor Capital, HRTG Partners, RWN Management, Doug Leone Family Fund, Breyer Capital and GordonMD Global Investments
私有 自建(M) ? ✓ — —
32 Osanni Bio 美国 US / San Francisco — — — 1 轮 2026-06-23 Series B $190M 190
Patient Square CapitalPatient Square Capital, Horowitz Group, Invus Opportunities and the Retinal Degeneration Fund
私有 混合(M) ? — —
33 LifeMine Therapeutics 美国 US / Cambridge MA Small molecules Other Phase 1 1 轮 2026-08-06 Series E $188M 188
Milky Way InvestmentsMilky Way Investments / RA Capital Management, GV, Arch Venture Partners / Milky Way Investments, Bezos Expeditions, Gates Frontier, RA Capital Management, Google Ventures, LoLa Capital Partners, GSK, Invus and ARCH Venture Partners
私有 自建(H) ? ✓ — —
34 Callio Therapeutics 美国 USA / Seattle WA Biologics Cancer Preclinical 1 轮 2025-03-03 Series A $187M 187
Frazier Life SciencesFrazier Life Sciences / Novo Holdings / Frazier Life Sciences, Jeito Capital, Novo Holdings, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI
私有 虚拟(M) ? ✓ — —
35 Braveheart Bio 美国 USA / San Francisco CA Small molecules Other Phase 3 1 轮 2025-11-05 Series A $185M 185
Andreessen Horowitz (a16z Bio + Health)Forbion, OrbiMed / Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital) and Frazier Life Sciences
上市 虚拟(H) 是 ✓ — —
36 Electra Therapeutics 美国 USA / South San Francisco, CA Biologics Multiple Phase 2 1 轮 2025-10-22 Series C $183M 183
NextechEQT Life Sciences, Nextech Invest / EQT Life Sciences, OrbiMed, RA Capital Management, Sanofi Ventures / Nextech, EQT Life Sciences, Sanofi, HBM Healthcare Investments, Mubadala Capital, OrbiMed, Redmile Group, New Leaf Venture Partners, Westlake BioPartners, Cormorant Asset Management, Blue Owl Capital and RA Capital Management
上市 混合(H) 是 @ELECTRA_Biotech 31
37 Celea Therapeutics 美国 USA / Boston MA Small molecules Other Phase 2 1 轮 2026-07-02 未披露轮 $180M 180
RA Capital ManagementRA Capital Management / RA Capital Management, Leaps by Bayer, PureTech Health, a “large, U.S.-based healthcare-focused fund” and a “leading sovereign wealth fund”
私有 虚拟(M) ? — —
38 cAMPfield Therapeutics 美国 USA / San Diego Small molecules Immune diseases Phase 2 1 轮 2026-06-18 Series A $180M 180
ForbionFrazier Life Sciences / Forbion, Novo Holdings, RA Capital Management
私有 虚拟(M) 是 ✓ — —
39 Timberlyne Therapeutics 美国 US / Biologics Immune diseases Phase 1 1 轮 2025-01-09 Series A $180M 180
AbingworthAbingworth, Bain Capital Life Sciences, Venrock Healthcare Capital Partners / Bain Capital Life Sciences / Led by Abingworth, Bain Capital Life Sciences and Venrock Healthcare Capital Partners, with Boyu Capital, Lilly Asia Ventures, Braidwell LP and 3H Health Investment
私有 虚拟(M) 是 ✓ — —
40 Antares Therapeutics 美国 USA / Boston MA Small molecules Cancer Preclinical 1 轮 2025-06-10 Series A $177M 177
Omega FundsAtlas Venture, Omega Funds, Lightspeed Venture Partners, BVF Partners, Cormorant Asset Management / Atlas Venture / Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, Cormorant Asset Management, Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures and Willett Advisors
私有 自建(H) ? — —
41 Tune Therapeutics 美国 US / Salt Lake City Cell or gene therapy Infectious diseases Phase 1
2 轮2025-01-12 Series B $175M
2025-01-13 Series B $175M
2025-01-13 Series B $175M 175
New Enterprise AssociatesNEA, Yosemite, Regeneron Ventures, Hevolution Foundation / NEA / Led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation
私有 自建(M) ? @tunetx_news 1.1k
42 Syremis Therapeutics 美国 US / Boston Multiple CNS disorders Phase 1 1 轮 2025-12-18 Series A $165M 165
Dexcel PharmaDexcel Pharma, Third Rock Ventures / Bain Capital Life Sciences, GV, Third Rock Ventures / Dexcel Pharma, Third Rock Ventures, Bain Capital Life Sciences, GV (Google Ventures), QVT and Pictet
私有 虚拟(L) ? ✓ — —
43 Atavistik Bio 美国 USA / Cambridge MA Small molecules Other Phase 1
2 轮2025-12-18 Series B $120M
2026-03-05 Series B $40M
2026-03-05 Series B $40M 160
Nextech InvestNextech Invest, The Column Group, Lux Capital and Regeneron Ventures / RA Capital Management
私有 自建(M) ? — —
44 Altesa BioSciences 美国 USA / Wayne PA Small molecules Other Phase 2 1 轮 2026-02-19 Series B $85M 160
ForbionForbion / Forbion, Sanofi, Medicxi, Pitango and Atlantic Partners
私有 虚拟(M) ? ✓ — —
45 Alveus Therapeutics 美国 USA / Philadelphia — — — 1 轮 2026-01-08 Series A $160M 160
Andera PartnersAndera Partners, New Rhein Healthcare Investors, Omega Funds, Sanofi Capital, Kurma Partners, Avego BioScience Capital and others
私有 虚拟(M) 是 ✓ — —
46 Epicrispr Biotechnologies 美国 USA / South San Francisco, CA Cell or gene therapy Rare diseases Phase 1
2 轮2025-03-26 Series B $68M
2026-08-11 Series C $90M
2026-08-11 Series C $90M 158
Octagon CapitalAlly Bridge Group, SOLVE FSHD and other investors / Octagon Capital, Janus Henderson Investors / Sanofi Ventures / Octagon Capital, Janus Henderson Investors, Fidelity Management & Research Company, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, funds managed by abrdn Inc., Angelini Ventures, Readout Capital and existing investors
私有 混合(H) 否 @EpicrisprBio 308
47 AIRNA 美国 USA / Cambridge MA Cell or gene therapy Rare diseases Preclinical 1 轮 2025-04-01 Series B $155M 155
Venrock Healthcare Capital PartnersVenrock Healthcare Capital Partners, Forbion / Arch Venture Partners / Venrock Healthcare Capital Partners, Forbion Growth, RTW Investments, Nextech Invest, ARCH Venture Partners, Forbion Ventures, ND Capital and other unnamed investors
私有 自建(M) ? @AirnaBio 0
48 Strand Therapeutics 美国 US / Boston Nucleic acids Cancer Phase 1 1 轮 2025-08-07 Series B $153M 153
KinnevikKinnevik / Eli Lilly and Company / Kinnevik, Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group, JIC-VGI, LG Technology Ventures, Gradiant Corporation, FPV Ventures, Playground Global, Eli Lilly, ANRI and Potentum
私有 混合(M) ? @StrandTx 2.3k
49 Arthrosi Therapeutics 美国 USA / Palo Alto CA — — — 1 轮 2025-10-08 Series E $153M 153
Prime Eight Capital LimitedPrime Eight Capital Limited, CR Biotech, HighLight Capital, HM Venture Partners, ReliantTech Limited and existing shareholders
被收购 虚拟(M) 是 ✓ — —
50 Matchpoint Therapeutics 美国 US / Cambridge MA Small molecules Immune diseases Preclinical 1 轮 2026-10-07 Series B $150M 150
Sanofi VenturesNextech Invest, Norwest / Sanofi Ventures, Atlas Venture
私有 自建(M) ? @matchpointtx 138
51 Atsena Therapeutics 美国 USA / Durham NC Cell or gene therapy Other Phase 1 1 轮 2025-04-02 Series C $150M 150
Bain CapitalBain Capital Life Sciences / Bain Capital Life Sciences, Sofinnova Investments / Bain Capital, Sofinnova Investments, Abingworth, Wellington Management, Lightstone Ventures, Foundation Fighting Blindness, Hatteras Venture Partners, Osage University Partners and the Manning Family Foundation
私有 混合(H) 否 — —
52 Latigo Biotherapeutics 美国 USA / Thousand Oaks, CA — — — 1 轮 2025-03-17 Series B $150M 150
Blue Owl CapitalBlue Owl Capital, Deep Track Capital, Access Biotechnology, Qatar Investment Authority and Sanofi Ventures
上市 混合(H) 是 @latigobio 2
53 Infinimmune 美国 USA / Alameda, CA Biologics Immune diseases Preclinical 1 轮 2026-08-11 Series A $65M 140
Regeneron VenturesRegeneron Ventures, Playground Global / RA Capital Management / Regeneron Ventures, Playground Global, RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital, Wild Tree Ventures, Merck Global Health Innovation Fund, Everbright Biofund, Civilization Ventures and Pear VC
私有 混合(H) 否 @infinimmune 139
54 Grin Therapeutics 美国 USA / New York, NY — — — 1 轮 2025-05-27 Series D $140M 140
Angelini Pharma and Blackstone Life ScieAngelini Pharma and Blackstone Life Sciences
私有 虚拟(M) ? ✓ — —
55 Sidewinder Therapeutics 美国 USA / San Diego, CA Biologics Cancer Preclinical 1 轮 2026-04-08 Series B $137M 137
Frazier Life SciencesFrazier Life Sciences, Novartis Venture Fund / OrbiMed, Samsara BioCapital, Alexandria Venture Investments / Frazier Life Sciences, Novartis Venture Fund, OrbiMed, Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund and Astellas Venture Management
私有 混合(L) ? — —
56 Slate Medicines 美国 US / Raleigh Biologics CNS disorders Preclinical 1 轮 2026-02-24 Series A $130M 130
RA Capital ManagementRA Capital Management, Forbion, Foresite Capital / RA Capital Management, Forbion / RA Capital Management, Forbion, Foresite Capital and an unnamed biotech investor
反向并购 虚拟(H) 是 ✓ — —
57 Angitia Biopharmaceuticals 美国 USA / Westlake Village CA Biologics Other Phase 2 1 轮 2026-02-05 Series D $130M 130
Frazier Life SciencesFrazier Life Sciences, Venrock Healthcare Capital Partners / RA Capital Management, Bain Capital Life Sciences, OrbiMed / Frazier Life Sciences, Venrock Healthcare Capital Partners, Ascenta Capital, certain funds and accounts managed by Blackrock, BVF Partners, Logos Capital, RA Capital Management, Wellington Management. Bain Capital Life Sciences, Elikon Venture, Janus Henderson Investors, 3H Healt
私有 自建(M) 是 — —
58 Corsera Health 美国 USA / Boston, MA Nucleic acids Other Phase 1
2 轮2025-09-02 Series N/A $50M
2026-01-07 Series A $80M
2026-01-07 Series A $80M 130
Clive MeanwellClive Meanwell, John Maraganore and other undisclosed individuals / Forbion, Population Health Partners / Forbion / Forbion, Population Health Partners and others
私有 虚拟(M) ? ✓ — —
59 Protego Biopharma 美国 USA / San Diego, CA Small molecules Rare diseases Phase 1 1 轮 2025-12-01 Series B $130M 130
Novartis Venture FundForbion, Novartis Venture Fund / Forbion / Novartis Venture Fund, Forbion, Omega Funds, Droia Ventures, YK Bioventures, Digitalis Ventures, Vida Ventures, MPM BioImpact, Lightspeed Venture Partners and Scripps Research
私有 自建(M) ? — —
60 Stylus Medicine 美国 US / Watertown MA Cell or gene therapy Multiple Preclinical 1 轮 2025-05-13 Series A $45M 130
RA Capital ManagementRA Capital, Eli Lilly and Company / RA Capital Management, Khosla Ventures, Chugai Venture Fund, Eli Lilly, Johnson & Johnson Innovation, the Myeloma Investment Fund and Tachyon Ventures
私有 自建(M) ? — —
61 SonoThera 美国 US / South San Francisco Cell or gene therapy Rare diseases Preclinical 1 轮 2026-06-10 Series B $125M 125
Vida VenturesVida Ventures / Vivo Capital, Arch Venture Partners, Alexandria Venture Investments, RA Capital Management / Vida Ventures, ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, ARCH Venture Partners, Alexandria Venture Investments, Duquesne Family Office, Illumina Ventures, Johnson & Johnson Innovation, Medical Excellence Capital, RA Cap
私有 自建(H) ? — —
62 Ray Therapeutics 美国 US / Berkeley, CA Cell or gene therapy Other Phase 1 1 轮 2026-04-21 Series B $125M 125
Janus Henderson InvestorsDeerfield Management, Novo Holdings / Janus Henderson Investors, with participation from new investors Adage Capital Management, Franklin Templeton, Invus and Marshall Wace, alongside follow-on support from existing backers 4BIO Capital, Deerfield Management, MRL Ventures Fund, Norwest, Novo Holdings and Platanus
私有 混合(M) 否 ✓ — —
63 Diagonal Therapeutics 美国 USA / Watertown, MA Biologics Rare diseases Preclinical 1 轮 2026-01-08 Series B $125M 125
Sanofi VenturesSanofi Ventures, Janus Henderson Investors / Sanofi Ventures, RA Capital Management, Atlas Venture / Sanofi Ventures, Janus Henderson Investors, Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management L.P., Woodline Partners LP, Atlas Venture, BVF Partners, Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, RV Invest, Velosity Capi
私有 自建(M) ? ✓ — —
64 Ambros Therapeutics 美国 USA / Irvine CA Biologics CNS disorders Phase 2
2 轮2025-12-16 Series A $125M
2025-12-17 Series A $125M
2025-12-17 Series A $125M 125
RA Capital ManagementRA Capital Management, Patient Square Capital's platform Enavate Sciences, Abiogen Pharma, Janus Henderson Investors, Arkin Bio, Balyasny Asset Management, Transhuman Capital, Adage Capital Partners and other dedicated life sciences investors / RA Capital Management, Enavate Life Sciences / RA Capital Management
私有 虚拟(M) 否 ✓ — —
65 Sling Therapeutics 美国 USA / Ann Arbor, MI Small molecules Eye diseases Phase 3 1 轮 2026-09-16 Series C $123M 123
ForbionForbion / Forbion, TPG Life Sciences Innovations and Sectoral Asset Management
私有 虚拟(M) ? ✓ — —
66 Create Medicines 美国 USA / Waltham, MA Cell or gene therapy Multiple Phase 1 1 轮 2026-05-14 Series B $122M 122
Newpath PartnersNewpath Partners, Arch Venture Partners, Hatteras Venture Partners / Arch Venture Partners / Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners, Alexandria Venture Investments and others
私有 混合(H) 是 — —
67 Merida Biosciences 美国 US / Cambridge MA Biologics Immune diseases Preclinical 1 轮 2025-04-08 Series A $121M 121
Bain Capital Life SciencesBain Capital Life Sciences, Third Rock Ventures / Bain Capital Life Sciences, Third Rock Ventures, GV / Bain Capital Life Sciences, BVF Partners, Third Rock Ventures, GV and Perceptive Xontogeny Venture Funds (PXV Funds)
被收购 自建(M) ? — —
68 Triana Biomedicines 美国 US / Lexington, MA Small molecules Cancer Preclinical 1 轮 2025-12-03 Series B $120M 120
RA Capital ManagementAscenta Capital, Bessemer Venture Partners / RA Capital Management, Atlas Venture / RA Capital Management, Atlas Venture, Lightspeed Venture Partners, Pfizer Ventures, Surveyor Capital
私有 自建(M) ? — —
69 Solve Therapeutics 美国 USA / San Diego, CA Biologics Cancer Phase 1 1 轮 2025-11-17 未披露轮 $120M 120
YosemiteYosemite / Alexandria Venture Investments / Yosemite, Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., SymBiosis, Alexandria Venture Investments, AyurMaya Capital Management, DC Global Ventures, General Atlantic and Citadel's Surveyor Capital
私有 自建(M) ? — —
70 Pelage Pharmaceuticals 美国 US / Los Angeles Small molecules Other Phase 2 1 轮 2025-10-15 Series B $120M 120
ARCH Venture PartnersArch Venture Partners, GV / ARCH Venture Partners, GV (Google Ventures), Main Street Advisors, Visionary Ventures and YK Bioventures
私有 虚拟(L) ? ✓ @PelagePharma 986
71 Ouro Medicines 美国 US / San Francisco Biologics Immune diseases Preclinical 1 轮 2025-01-10 Series A $120M 120
TPG Life Sciences InnovationsTPG Life Science Innovations, NEA, Norwest Venture Partners / NEA / Co-led by TPG Life Sciences Innovations, NEA and Norwest Venture Partners, with Monograph Capital, GSK, UPMC Enterprises, Boyu/Zoo Capital, LongRiver Investments and other unnamed investors
被收购 虚拟(H) 是 ✓ — —
72 Claris Biotherapeutics 美国 USA / Jersey City, NJ Small molecules Eye diseases Phase 1 1 轮 2026-07-28 Series B $118M 118
Samsara BioCapitalSamsara BioCapital, Catalio Capital Management / Sofinnova Investments, Novo Holdings
私有 虚拟(M) 否 ✓ — —
73 BrainChild Bio 美国 USA / Seattle WA — — — 1 轮 2026-09-08 Series A $116M 116
Undisclosed private family fund and founUndisclosed private family fund and foundation, Seattle Children’s and WRF Capital
私有 混合(H) 否 — —
74 ILiAD Biotechnologies 美国 USA / Jupiter, FL Other Infectious diseases Phase 2 1 轮 2026-02-10 Series B $115M 115
RA Capital ManagementRA Capital Management / RA Capital Management, Janus Henderson Investors, BNP Paribas Asset Management and others
私有 虚拟(M) ? — —
75 Aspen Neuroscience 美国 USA / San Diego Cell or gene therapy CNS disorders Phase 1 1 轮 2025-11-20 Series C $115M 115
OrbiMedOrbiMed, Arch Venture Partners, Frazier Life Sciences, Revelation Partners / OrbiMed, Arch Venture Partners / OrbiMed, ARCH Venture Partners, Frazier Life Sciences, Revelation Partners, Medical Excellence Capital, S32, Axon Ventures, LYFE Capital, LifeForce Capital, Gilead's Kite Pharma, Balyasny Asset Management, Cormorant Asset Management, Prebys Ventures and others
私有 自建(H) 否 @AspenNeuro 384
76 Glycomine 美国 USA / San Carlos, CA Small molecules Rare diseases Phase 2 1 轮 2025-04-16 Series C $115M 115
CTI Life Sciences FundCTI Life Sciences Fund, abrdn, Advent Life Sciences / Novo Holdings, Sanofi Ventures / CTI Life Sciences Fund, funds managed by abrdn, Advent Life Sciences, Novo Holdings, Sanofi Ventures, Abingworth, RiverVest Venture Partners, Sanderling Ventures, Chiesi Ventures, Remiges Ventures and Asahi Kasei Ventures
私有 虚拟(M) ? — —
77 Wugen 美国 US / St. Louis — — — 1 轮 2025-08-27 Series N/A $115M 115
Fidelity Management & Research CompanyFidelity Management & Research Company, with RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, Aisling Capital Management and others
私有 混合(M) 否 — —
78 RayThera 美国 US / San Diego Small molecules Immune diseases Preclinical 1 轮 2025-04-04 Series A $110M 110
Foresite CapitalForesite Capital, OrbiMed / OrbiMed / Foresite Capital, OrbiMed Advisors and TTM Capital
被收购 虚拟(L) ? — —
79 Curevo 美国 USA / Seattle, WA Other Infectious diseases Phase 2 1 轮 2025-03-17 Series B $110M 110
OrbiMedMedicxi / OrbiMed, RA Capital Management, Sanofi Ventures
被收购 虚拟(M) 否 — —
80 Terremoto Biosciences 美国 US / South San Francisco Small molecules Cancer Phase 1 1 轮 2026-04-15 Series C $108M 108
RA Capital ManagementRA Capital, OrbiMed, Third Rock Ventures, Novo Holdings / RA Capital Management, Deep Track Capital, Osage University Partners, BeOne Medicines, OrbiMed, Third Rock Ventures, Novo Holdings and Cormorant Asset Management
私有 自建(H) ? — —
81 EpiBiologics 美国 USA / South San Francisco, CA Biologics Multiple Preclinical 1 轮 2026-01-08 Series B $107M 107
Google VentureGV, Johnson & Johnson Innovation / GV, Samsara BioCapital, Polaris Partners, Vivo Capital / Google Venture, Johnson & Johnson, Novartis Venture Fund, Aulis Capital, Avego BioScience Capital, Samsara BioCapital, Polaris Partners, Digitalis Ventures, Taiho Ventures, Vivo Capital, Codon Capital and Mission BioCapital
私有 自建(L) ? — —
82 Profluent 美国 US / Emeryville — — — 1 轮 2025-11-19 Series N/A $106M 106
Altimeter CapitalAltimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners and Air Street Capital
私有 混合(H) ? ✓ @ProfluentBio 4.2k
83 Tortugas Neuroscience 美国 US / — — — 1 轮 2026-04-21 Seed/Series A $106M 106
Cure VenturesCure Ventures, The Column Group and AN Venture Partners
私有 虚拟(M) ? ✓ — —
84 Kinaset Therapeutics 美国 USA / Boston, MA Small molecules Other Phase 2
2 轮2026-01-09 Series B $103M
2026-01-10 Series B $103M
2026-01-10 Series B $103M 103
RA Capital ManagementRA Capital Management / EQT Life Sciences, RA Capital Management, Atlas Venture / RA Capital Management, Forge Life Science Partners, EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, Sixty Degree Capital, Atlas Venture, 5AM Ventures and Gimv
私有 虚拟(M) ? ✓ — —
85 Neurona Therapeutics 美国 US / San Diego Cell or gene therapy CNS disorders Phase 2 1 轮 2025-04-03 未披露轮 $102M 102
Fidelity Management & Research CompanyAlexandria Venture Investments / Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, Cormorant Asset Management, Schroders Capital, LYFE Capital, Euclidean Capital, UCB Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments and Spur Capital Partners
被收购 自建(H) ? ✓ — —
86 Ethyreal Bio 美国 USA / Cambridge, MA Biologics Eye diseases Preclinical 1 轮 2026-06-10 未披露轮 $101M 101
The Series A was co-led by Atlas VentureAtlas Venture, Medicxi Ventures / Atlas Venture / The Series A was co-led by Atlas Venture and Medicxi Ventures, alongside Nandi Life Sciences and Checkpoint Capital. The Series B included all Series A investors and was led by Avoro Capital
私有 虚拟(L) ? — —
87 Nilo Therapeutics 美国 US / New York Undisclosed Immune diseases Preclinical 1 轮 2025-10-08 Series A $101M 101
The Column GroupLux Capital, The Column Group, DCVC Bio / Alexandria Venture Investments / The Column Group, DCVC Bio, Lux Capital, the Gates Foundation and Alexandria Venture Investments
私有 自建(M) ? — —
88 City Therapeutics 美国 USA / Cambridge, MA Nucleic acids Other Phase 1 1 轮 2026-06-08 Series B $100M 100
Viking Global InvestorsArch Venture Partners, Sofinnova Investments / Viking Global Investors, Sofinnova Investments, Casdin Capital, NYBC Ventures, ARCH Venture Partners, Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures and others
上市 混合(H) ? — —
89 Neomorph 美国 US / San Diego Small molecules Cancer Phase 1 1 轮 2026-04-13 Series B $100M 100
Deerfield ManagementDeerfield Management / Deerfield Management, Alexandria Venture Investments / Deerfield Management, Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute and others
私有 自建(M) ? — —
90 Stipple Bio 美国 USA / Cambridge, MA Biologics Cancer Preclinical
2 轮2026-04-06 Series A $100M
2026-04-08 Series A $100M
2026-04-08 Series A $100M 100
RA CapitalRA Capital Management, Nextech Invest, a16z Bio + Health / RA Capital Management, GV / RA Capital, a16z Bio+Health, Nextech Invest, Emerson Collective Investments, GV, LoLa Capital Partners and GordonMD Global Investments
私有 混合(M) 否 — —
91 Ambrosia Biosciences 美国 USA / Boulder CO Small molecules Metabolic diseases Preclinical 1 轮 2026-03-31 Series B $100M 100
Blue Owl Healthcare OpportunitiesBlue Owl Healthcare Opportunities, Redmile, Deep Track Capital / Samsara BioCapital / Blue Owl Healthcare Opportunities, Redmile, Deep Track Capital, BVF Partners Boulder Ventures, Janus Henderson Investors, Samsara BioCapital and an undisclosed institutional investor
私有 自建(H) ? — —
92 Vima Therapeutics 美国 US / Boston Small molecules CNS disorders Phase 1
2 轮2025-05-29 Series A $60M
2026-03-12 Series A $40M
2026-03-12 Series A $40M 100
Atlas VentureAtlas Venture / Atlas Venture, Access Industries and Canaan
私有 虚拟(M) ? — —
93 Avalyn Pharma 美国 USA / Massachusetts Small molecules Other Phase 2 1 轮 2025-07-22 Series D $100M 100
Suvretta Capital ManagementSuvretta Capital Management, SR One / F-Prime Capital, Novo Holdings / Suvretta Capital Management, SR One, Novo Holdings, F-Prime, Perceptive Xontogeny Venture Funds, Norwest, Eventide Asset Management, Wellington Management, Vida Ventures, Catalio Capital Management, RiverVest Venture Partners, Pivotal bioVenture Partners, TPG Biotech, Hamilton Square Partners Management, LP (HSq), Rock Springs Ca
上市 虚拟(H) ? ✓ — —
94 Umoja Biopharma 美国 US / Boulder CO Cell or gene therapy Multiple Phase 1 1 轮 2025-01-14 Series C $100M 100
Double Point Ventures and DCVC BioDouble Point Ventures, DCVC Bio / MPM BioImpact, Alexandria Venture Investments / Co-led by Double Point Ventures and DCVC Bio, with ARK Invest, Cormorant Asset Management, MPM Capital, Qiming Venture Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank Vision Fund 2, CaaS Capital, Emerson Collective Investments managed by Yosemite, K2 HealthVentures, Myeloma Investment Fund, Univ
私有 自建(H) ? @UmojaBiopharma 316
95 Addition Therapeutics 美国 USA / South San Francisco — — — 1 轮 2025-12-17 Series N/A $100M 100
SR OneSR One, Pivotal Life Sciences, Abingworth, Osage University Partners, the Gates Foundation and BEVC
私有 自建(H) ? — —
96 Rakuten Medical 美国 US / San Diego — — — 1 轮 2026-01-07 Series F $100M 100
TaiAx Life Science FundTaiAx Life Science Fund, Daiwa Securities, Mitsui Sumitomo Insurance, Sumitomo Mitsui Banking, ABIES Capital, Nexus CVC, OEP Group, SBI Group, Rakuten Group and Rakuten Medical CEO Mickey Mikitani
私有 混合(M) 否 — —
97 Atalanta Therapeutics 美国 USA / Boston MA Nucleic acids CNS disorders Preclinical 1 轮 2025-01-28 Series B $97M 97
EQT Life SciencesEQT Life Sciences, Sanofi Ventures / EQT Life Sciences, F-Prime Capital, Sanofi Ventures / EQT Life Sciences, Sanofi Ventures, F-Prime Capital, Novartis Venture Fund, RiverVest Venture Partners, funds managed by abrdn, Pictet Alternative Advisors, the Mirae Asset Financial Group and the GHR Foundation
私有 自建(M) ? — —
98 TORL BioTherapeutics 美国 US / Los Angeles — — — 1 轮 2025-10-07 Series C $96M 96 Unknown 私有 虚拟(M) ? — —
99 Poplar Therapeutics 美国 US / Boston Biologics Immune diseases Phase 1
2 轮2026-01-07 Series A $50M
2026-03-03 Series A $45M
2026-03-03 Series A $45M 95
SR OneSR One, Vida Ventures and Platanus / Janus Henderson Investors / RA Capital Management
私有 虚拟(M) ? — —
100 Sparrow Therapeutics 美国 US / Portland OR Small molecules Metabolic diseases Phase 2 1 轮 2025-09-24 Series B $95M 95
RA Capital ManagementRA Capital Management, Forbion / RA Capital Management, Forbion, OrbiMed, RiverVest and US Venture Partners
私有 虚拟(M) ? — —
101 Newleos Therapeutics 美国 US / Boston Small molecules CNS disorders Phase 1 1 轮 2025-02-13 Series A $94M 94
Goldman Sachs AlternativesGoldman Sachs Alternatives / Novo Holdings / Goldman Sachs Alternatives, Longwood Fund, Novo Holdings, DCVC Bio and Arkin Bio Capital
私有 虚拟(M) ? ✓ — —
102 Circle Pharma 美国 USA / South San Francisco, CA Small molecules Cancer Phase 1 1 轮 2026-09-16 Series E $93M 93
The Column GroupThe Column Group / Eli Lilly and Company, RA Capital Management / The Column Group, Nextech Invest, RA Capital Management, Euclidean Capital and Eli Lilly and Company
私有 混合(M) 是 ✓ @CirclePharma 73
103 Memento Medicines 美国 US / Boston Biologics Eye diseases Preclinical 1 轮 2026-06-18 Series A $93M 93
ForbionForbion, RA Capital Management, Avego BioScience Capital / Forbion, RA Capital Management, Sanofi Ventures, Samsara BioCapital / Forbion, RA Capital Management, Avego BioScience Capital, Sanofi Ventures and Samsara BioCapital
私有 虚拟(M) ? ✓ — —
104 Contraline 美国 USA / Charlottesville, VA Other Other Phase 2 1 轮 2026-06-02 Series B $93M 93
BVF PartnersBVF Partners, RA Capital Management / RA Capital Management, GV / BVF Partners, RA Capital Management, Google Ventures, Lumira Ventures, Invus and others
私有 自建(M) ? @contraline 637
105 Character Biosciences 美国 USA / Jersey City, NJ — — — 1 轮 2025-03-25 Series B $93M 93
aMoonaMoon, Luma Group, Bausch + Lomb, Jefferson Life Sciences, Endeavors, Catalio Capital Management, S32 and KdT Ventures
私有 自建(M) ? — —
106 Setara Biosciences 美国 USA / San Diego, CA Small molecules CNS disorders Phase 1 1 轮 2026-10-30 Series A $90M 90 Deerfield Management 私有 自建(L) ? — —
107 Attovia Therapeutics 美国 USA / South San Francisco Biologics Immune diseases Phase 1 1 轮 2025-04-15 Series C $90M 90
Deep Track CapitalDeep Track Capital / venBio, Sanofi Ventures / Deep Track Capital, Vida Ventures, Sanofi Ventures, Mirae Asset Capital Life Science, Frazier Life Sciences, venBio, Goldman Sachs Alternatives, Nextech Ventures, Cormorant Asset Management, EcoR1 Capital, Marshall Wace and Illumina Ventures
上市 混合(H) 是 — —
108 Bambusa Therapeutics 美国 USA / Boston MA Biologics Immune diseases Preclinical 1 轮 2025-02-14 Series A $90M 90
RA Capital ManagementRA Capital Management / RA Capital Management, Janus Henderson Investors, Redmile Group, Invus, ADAR1 Capital Management, and other unnamed existing investors
上市 虚拟(H) 是 ✓ — —
109 Syndeio Biosciences 美国 USA / Indianapolis, IN — — — 1 轮 2025-05-27 Series N/A $90M 90
Catalio Capital ManagementCatalio Capital Management, Innoviva, Tenmile, Luson Bioventures, Palo Santo, and AbbVie and Eli Lilly as strategic shareholders
私有 混合(M) ? — —
110 Pinnacle Medicines 美国 USA / Doylestown, PA Biologics Multiple Preclinical 1 轮 2026-03-26 Series B $89M 89
OrbiMedLAV, Foresite Capital / OrbiMed, RA Capital Management
私有 混合(M) ? ✓ — —
111 QuantX Biosciences 美国 US / Princeton NJ Small molecules Immune diseases Preclinical 1 轮 2026-02-09 Series B $85M 85
LAVSanofi Ventures, LAV / Sanofi Ventures / LAV, Sanofi Ventures, Hongshan and others
私有 虚拟(M) ? ✓ — —
112 Tenpoint Therapeutics 美国 US / Small molecules Other Marketed
2 轮2026-01-28 Series B $85M
2026-01-29 Series B $85M
2026-01-29 Series B $85M 85
Janus HendersonJanus Henderson Investors, EQT Nexus, Hillhouse, British Business Bank / EQT Life Sciences, Sofinnova Partners, F-Prime Capital / Janus Henderson, EQT Nexus, Hillhouse, British Business Bank, EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio and Wille
私有 虚拟(M) 否 @Tenpoint_Tx 638
113 BlossomHill Therapeutics 美国 USA / San Diego Small molecules Cancer Phase 1 1 轮 2025-12-10 Series B $84M 84
Janus Henderson InvestorsJanus Henderson Investors, Brahma Capital, BioTrack Capital / OrbiMed / Janus Henderson Investors, Brahma Capital, BioTrack Capital, Cormorant Asset Management, OrbiMed, Plaisance Capital Management and Vivo Capital
上市 混合(H) 是 — —
114 Mendra 美国 US / San Francisco Bay Area Undisclosed Rare diseases Preclinical 1 轮 2026-01-22 Series A $82M 82
OrbiMedOrbiMed, 8VC, 5AM Ventures / OrbiMed / OrbiMed, 8VC, 5AM Ventures, Lux Capital and Wing VC
私有 虚拟(M) ? ✓ ✓ — —
115 Azalea Therapeutics 美国 USA / Berkeley CA Cell or gene therapy Multiple Preclinical 1 轮 2025-11-04 Seed / Series A $82M 82
Third Rock VenturesThird Rock Ventures / Third Rock Ventures, RA Capital Management / Third Rock Ventures, RA Capital Management, Yosemite, Sozo Ventures and unnamed individual investors
私有 自建(H) ? — —
116 R1 Therapeutics 美国 US / Redwood City Small molecules Other Phase 2
2 轮2026-03-17 Series A $78M
2026-09-30 Series A $3M
2026-09-30 Series A $3M 80
AbingworthAbingworth, F-Prime Capital, DaVita Venture Group, Curie.Bio, SymBiosis and U.S. Renal Care / Samsara BioCapital
私有 虚拟(M) 是 ✓ — —
117 Proxima 美国 USA / New York, NY Small molecules Undisclosed Preclinical 1 轮 2026-01-13 Seed $80M 80
DCVCDCVC / Alexandria Venture Investments / DCVC, NVentures (NVIDIA’s venture capital arm), Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments, Modi Ventures and others
私有 混合(M) ? ✓ — —
118 A2 Biotherapeutics 美国 USA / Agoura Hills CA Cell or gene therapy Cancer Phase 1 1 轮 2025-01-09 Series C $80M 80
A syndicate of investors that includes TSamsara BioCapital / A syndicate of investors that includes The Column Group and Samsara BioCapital
私有 自建(H) 否 — —
119 Life Biosciences 美国 US / Boston — — — 1 轮 2026-04-08 Series B $80M 80 Not disclosed 私有 虚拟(M) 否 @lifebiosciences 24k
120 Peptilogics 美国 US / Pittsburgh — — — 1 轮 2025-10-16 Series B2 $78M 78
Presight CapitalPresight Capital, Thiel Bio, Founders Fund, AMR Action Fund, Narya Capital and Beyond Ventures
私有 虚拟(L) ? @Peptilogics 353
121 InduPro 美国 USA / Seattle, WA Biologics Cancer Phase 1 1 轮 2026-08-12 Series B $77M 77
The Column GroupThe Column Group / Sanofi Ventures, Eli Lilly and Company / The Column Group, Vida Ventures, MRL Ventures Fund (the therapeutics-focused venture fund of Merck & Co., Inc.), Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi and Eli Lilly and Company
私有 自建(M) ? — —
122 Crossbow Therapeutics 美国 USA / Cambridge, MA Biologics Cancer Phase 1 1 轮 2026-03-18 Series B $77M 77
Taiho VenturesTaiho Ventures, Arkin Bio Capital / MPM BioImpact, Polaris Partners, Eli Lilly and Company / Taiho Ventures, Arkin Bio Capital, Sixty Degree Capital, Hamilton Square Partners Management LP, LifeLink Ventures, Libbs Ventures, Blood Cancer United’s Therapy Acceleration Program, MPM BioImpact, Pfizer Ventures, BVF Partners, Polaris Partners, Eli Lilly and Mirae Asset Venture Investment
私有 自建(M) ? — —
123 Mediar Therapeutics 美国 US / Boston Biologics Immune diseases Phase 2 1 轮 2026-01-07 Series B $76M 76
Amplitude VenturesAmplitude Ventures, ICG / Sofinnova Partners
私有 混合(M) 否 ✓ — —
124 BigHat Biosciences 美国 USA / San Mateo CA Biologics Cancer Phase 1 1 轮 2026-09-24 Series C $75M 75
Alexandria Venture InvestmentsDFJ Growth, Premji Invest / Alexandria Venture Investments, Eli Lilly and Company
私有 自建(H) ? ✓ @BigHatBio 1.2k
125 Lycia Therapeutics 美国 US / South San Francisco Biologics Immune diseases Preclinical 1 轮 2026-06-25 Series D $75M 75
Janus Henderson InvestorsJanus Henderson Investors, Balyasny Asset Management / OrbiMed, Eli Lilly and Company / Janus Henderson Investors, Balyasny Asset Management, Adage Capital Management, HBM Healthcare Investments, OrbiMed, Eli Lilly, Franklin Templeton, Invus, RTW Investments and Venrock Healthcare Capital Partners
上市 混合(H) 是 @LyciaTx 201
126 Caldera Therapeutics 美国 USA / Cambridge MA Biologics Immune diseases Phase 1 1 轮 2026-01-14 Series A $75M 75 Atlas Venture, venBio 反向并购 虚拟(H) 是 ✓ — —
127 SpyGlass Pharma 美国 US / Aliso Viejo CA Other Eye diseases Phase 2 1 轮 2025-06-02 Series D $75M 75
Sands CapitalSands Capital / NEA, RA Capital Management, Samsara BioCapital / Sands Capital, New Enterprise Associates, RA Capital, Vensana Capital, Samsara BioCapital and Vertex Ventures HC
上市 混合(M) 否 @SpyGlassPharma 40
128 Normunity 美国 US / Branford CT Biologics Cancer Preclinical 1 轮 2025-01-13 Series B $75M 75
Samsara BioCapital and Enavate SciencesSamsara BioCapital, Enavate Sciences / Samsara BioCapital, Sanofi Ventures / Co-led by Samsara BioCapital and Enavate Sciences, with participation from Regeneron Ventures, Pfizer Ventures, YK Bioventures, Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group and Connecticut Innovations
私有 虚拟(M) ? @normunity 34
129 Neok Bio 美国 US / California (South San Francisco) — — — 1 轮 2025-11-03 Series A $75M 75 ABL Bio 私有 虚拟(M) ? ✓ — —
130 Nura Bio 美国 US / South San Francisco Small molecules CNS disorders Phase 1 1 轮 2026-06-22 Series B $74M 74
The Column GroupThe Column Group / Sanofi Ventures, Samsara BioCapital / The Column Group, Euclidean Capital, Samsara BioCapital and Sanofi Ventures
私有 自建(M) ? — —
131 Arbor Biotechnologies 美国 USA / Cambridge MA Cell or gene therapy Multiple Preclinical 1 轮 2025-03-18 Series C $74M 74
Arch Venture Partners and TCGXArch Venture Partners / Led by Arch Venture Partners and TCGX, with new investors QIA, Partners Investment, Revelation Partners and Kerna Ventures joining alongside other existing investors
私有 自建(H) ? @arbortx 551
132 Moonwalk Biosciences 美国 US / South San Francisco Nucleic acids Metabolic diseases Preclinical 1 轮 2026-09-08 Series B $70M 70
Alpha WaveArch Venture Partners, Eli Lilly and Company / Alpha Wave, YK Bioventures, Eli Lilly, Gaorong Ventures, Arch Venture Partners, Khosla Ventures and Future Ventures
私有 混合(M) 是 @moonwalkbio 17
133 Ratio Therapeutics 美国 US / Boston Radiopharmaceuticals Cancer Phase 1 1 轮 2026-07-31 Series C $70M 70
Duquesne Family OfficeEli Lilly and Company / Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company and Wasatch Group
私有 混合(H) 否 @Ratio_Tx 138
134 Prolynx 美国 US / San Francisco Bay Area Biologics Metabolic diseases Preclinical 1 轮 2025-12-11 Series A $70M 70
5AM Ventures5AM Ventures, OrbiMed / OrbiMed / 5AM Ventures, OrbiMed and Monograph Capital
私有 混合(H) 否 — —
135 Excelsior Sciences 美国 USA / New York, NY Small molecules Undisclosed Preclinical 1 轮 2025-12-03 Series A $70M 70
Deerfield ManagementDeerfield Management, Khosla Ventures, Sofinnova Partners / Deerfield Management, Sofinnova Partners, Eli Lilly and Company
私有 自建(H) 否 ✓ — —
136 Excellergy 美国 USA / California (Bay Area) Biologics Immune diseases Preclinical 1 轮 2025-10-13 Series A $70M 70
Samsara BioCapitalSamsara BioCapital / Samsara BioCapital, Red Tree Venture Capital and Decheng Capital
被收购 虚拟(M) ? — —
137 Tempero Bio 美国 US / California — — — 1 轮 2025-03-24 Series B $70M 70
8VC8VC, Aditum Bio, Khosla Ventures and other unnamed investors
不明 虚拟(M) ? ✓ — —
138 XyloCor Therapeutics 美国 USA / King of Prussia, PA Cell or gene therapy Other Phase 2 1 轮 2025-01-07 Series B $68M 68
New investor Jeito CapitalJeito Capital / EQT Life Sciences / New investor Jeito Capital and existing institutional investors EQT, Fountain Healthcare Partners and Lumira Ventures
私有 虚拟(M) ? — —
139 Fore Biotherapeutics 美国 USA / Philadelphia, PA Small molecules Cancer Phase 2 1 轮 2026-07-07 Series D $67M 67 SR One, Medicxi, SymBiosis / OrbiMed 私有 虚拟(H) ? @ForeBiotx 90
140 Hillstar Bio 美国 USA / Boston, MA Biologics Immune diseases Preclinical
2 轮2025-03-25 Series A $67M
2025-03-26 Series A $67M
2025-03-26 Series A $67M 67
Droia VenturesDroia Ventures, Frazier Life Sciences, Novo Holdings, LifeArc Ventures and Hummingbird Bioscience / Novo Holdings, Droia Ventures, Frazier Life Sciences, LifeArc Ventures, Hummingbird Bioscience / Novo Holdings
私有 自建(H) ? — —
141 Cartography Biosciences 美国 USA / South San Francisco — — — 1 轮 2025-10-02 Series B $67M 67
Pfizer VenturesPfizer Ventures, LG Corp, Amgen Ventures, Finchley H.V., Global BioAccess Fund, Lotte Holdings CVC, Andreessen Horowitz (a16z) Bio + Health, 8VC, Wing Venture Capital, Catalio Capital Management, AME Cloud Ventures, ARTIS Ventures and Gaingels
私有 自建(H) ? ✓ @CartographyBio 478
142 Actio Biosciences 美国 USA / San Diego Small molecules Rare diseases Phase 1 1 轮 2025-06-18 Series B $66M 66
Regeneron VenturesRegeneron Ventures, Deerfield Management / Deerfield Management / Regeneron Ventures, Deerfield Management, Canaan, Droia Ventures and Euclidean Capital
被收购 自建(M) ? — —
143 RegCell 美国 USA / Emeryville, CA — — — 1 轮 2026-09-15 A and grant funding $66M 66
Playground GlobalPlayground Global, Global Brain, Mitsui Chemicals, LG Technology Ventures, Alumni Ventures, Medical Incubator Japan, Fast Track Initiative, The University of Tokyo Edge Capital Partners, Osaka University Venture Capital, Kyoto iCAP and Japan’s Agency for Medical Research and Development
私有 自建(L) ? — —
144 Boulevard Bio 美国 USA / New York, NY Biologics Immune diseases Phase 1 1 轮 2026-08-12 未披露轮 $65M 65 Deerfield Management 私有 虚拟(M) 是 ✓ — —
145 Gate Bioscience 美国 USA / Brisbane, CA Small molecules Multiple Preclinical 1 轮 2025-11-13 Series B $65M 65
ForbionForbion / Forbion, Eli Lilly and Company, Versant Ventures, Arch Venture Partners, GV / Forbion, Eli Lilly, Versant Ventures, Andreessen Horowitz (a16z) Bio + Health, GV and ARCH Venture Partners
私有 自建(M) ? — —
146 Dualitas 美国 USA / South San Francisco, CA Biologics Immune diseases Preclinical 1 轮 2025-09-16 Series A $65M 65
Versant VenturesVersant Ventures, Qiming Venture Partners USA / Versant Ventures, Alexandria Venture Investments, Eli Lilly and Company / Versant Ventures, Qiming Venture Partners USA, SV Health Investors, Chugai Venture Fund, Eli Lilly and Alexandria Venture Investments
私有 自建(M) ? — —
147 Helicore Biopharma 美国 USA / California Biologics Metabolic diseases Preclinical 1 轮 2025-01-28 Series A $65M 65
Founding investor Versant VenturesVersant Ventures, OrbiMed / Founding investor Versant Ventures, OrbiMed, Longitude Capital and Wellington Management
不明 虚拟(M) ? — —
148 Ampersand Biomedicines 美国 USA / Cambridge MA — — — 1 轮 2025-03-19 Series B $65M 65
Flagship PioneeringFlagship Pioneering, Eli Lilly and additional unnamed new investors
私有 自建(H) ? ✓ @AmpersandBio 118
149 Triveni Bio 美国 US / Watertown MA — — — 1 轮 2026-06-17 Series C $65M 65
Ascenta Capital and Janus Henderson InveAscenta Capital and Janus Henderson Investors, with participation from Deep Track Capital and existing investors
私有 自建(H) ? — —
150 TwoStep Therapeutics 美国 USA / San Carlos, CA — — — 1 轮 2026-09-09 Series A $62M 62
Insight PartnersInsight Partners, Medical Excellence Capital, M Ventures (the venture capital arm of Merck KGaA), Pfizer Ventures, NFX, 2048 Ventures, Stanford University and others
私有 自建(L) ? — —
151 Oblenio Bio 美国 US / Cambridge MA Biologics Immune diseases Preclinical 1 轮 2026-06-25 Series B $62M 62
Pfizer VenturesPfizer Ventures / GV / Pfizer Ventures, Deep Track Capital, GV and Aditum Bio
私有 虚拟(H) 是 ✓ — —
152 Light Horse Therapeutics 美国 USA / San Diego, CA Small molecules Cancer Preclinical 1 轮 2025-01-09 Series A $62M 62
Versant VenturesVersant Ventures / Versant Ventures, Mubadala Capital, Bristol Myers Squibb, Taiho Ventures and AbbVie
私有 自建(M) ? — —
153 Plexium 美国 US / San Diego — — — 1 轮 2025-08-28 Series N/A $60M 60 N/A 私有 混合(H) 是 ✓ @PlexiumInc 1
154 Superluminal Medicines 美国 US / Boston Small molecules Metabolic diseases Preclinical 1 轮 2026-09-03 Series B $60M 60
BVF Partners L.PBVF Partners / RA Capital Management, Eli Lilly and Company / BVF Partners L.P., Deep Track Capital, Perceptive Advisors, RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley and Gaingels
私有 混合(H) ? @superluminalrx 7
155 Link Cell Therapies 美国 US / California (Bay Area) Cell or gene therapy Cancer Preclinical 1 轮 2025-12-15 Series A $60M 60
Samsara BioCapitalJohnson & Johnson Innovation / Samsara BioCapital / Samsara BioCapital, Sheatree Capital, Johnson & Johnson Innovation, Bristol Myers Squibb, Kyowa Kirin, Wing Venture Capital and Sherpa Healthcare Partners
私有 混合(M) 是 — —
156 Avenzo Therapeutics 美国 USA / San Diego Small molecules Cancer Phase 1 1 轮 2025-09-22 Series B $60M 60
OrbiMedOrbiMed, SR One / OrbiMed, NEA / OrbiMed, SR One, Longwood Fund, Foresite Capital, Lilly Asia Ventures, Surveyor Capital (a Citadel company), New Enterprise Associates, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital and Quan Capital
反向并购 虚拟(H) 是 ✓ — —
157 Gilgamesh Pharma 美国 USA / New York, NY — — — 1 轮 2026-03-25 Series A $60M 60
Satori Neuro plus newSatori Neuro plus new and existing institutional investors including Prime Movers Lab
私有 虚拟(H) 是 ✓ — —
158 BreezeBio 美国 USA / South San Francisco CA — — — 1 轮 2026-02-25 Series B $60M 60
Yuanta InvestmentYuanta Investment, DSC Investment, SV investment, Kiwoom Investment, STIC Ventures, Top Harvest Capital, DAYLI Partners, Pathway Investment, Loftyrock Investment, Korea Investment Partners, WOORI Venture Partners, KDB Silicon Valley and ACVC Partners
私有 自建(H) ? — —
159 Breakthru Medicine 美国 USA / Phoenix AZ — — — 1 轮 2026-01-29 Series A $60M 60 N/A 私有 虚拟(M) ? ✓ — —
160 Cytotheryx 美国 USA / Minnesota — — —
2 轮2026-01-12 Series A $60M
2026-01-16 Series A $60M
2026-01-16 Series A $60M 60
Ouroboros Family Founders Fund IOuroboros Family Founders Fund I / Ouroboros Family Founders Fund I, LP
私有 自建(H) 否 — —
161 Allay Therapeutics 美国 USA / Burlingame CA Small molecules CNS disorders Phase 2 1 轮 2025-06-05 Series D $58M 58
Lightstone VenturesLightstone Ventures, ClavystBio / NEA / Lightstone Ventures, ClavystBio, NEA, Arboretum Ventures, Vertex Growth, Vertex Ventures Healthcare, Brandon Capital, IPD Capital, EDBI and SGInnovate, and HSBC Innovation Banking
私有 自建(M) 否 @allaytx 33
162 Imbria Pharmaceuticals 美国 USA / Boston, MA Small molecules Other Phase 2 1 轮 2025-04-10 Series B $58M 58
Deep Track CapitalDeep Track Capital / RA Capital Management / Deep Track Capital, AN Ventures, Catalio Capital Management, Cytokinetics, RA Capital Management and SV Health Investors
私有 虚拟(H) ? @ImbriaPharma 45
163 Typewriter Therapeutics 美国 US / Cambridge MA Cell or gene therapy Multiple Preclinical 1 轮 2026-09-02 Series A $56M 56
AN Venture PartnersAN Venture Partners, RA Capital Management / RA Capital Management
私有 自建(M) ? — —
164 Tectora Therapeutics 美国 US / Small molecules Immune diseases Preclinical 1 轮 2026-09-09 Series A $55M 55
New Enterprise Associates and RA CapitalRA Capital Management, NEA / New Enterprise Associates and RA Capital Management
私有 虚拟(M) ? ✓ — —
165 Aeovian Pharmaceuticals 美国 USA / Pasadena CA Small molecules CNS disorders Phase 1 1 轮 2025-12-16 Series B $55M 55
Luma Group. CTI Life Sciences FundLuma Group, CTI Life Sciences Fund / Sofinnova Investments, venBio / Luma Group. CTI Life Sciences Fund, Foresite Capital, SymBiosis, the TSC Alliance Endowment Fund, Wilson Sonsini, Apollo Health Ventures, Hevolution, Sofinnova Investments and venBio
私有 虚拟(M) ? — —
166 Renasant Bio 美国 US / California Small molecules Other Preclinical 1 轮 2025-07-10 Seed $55M 55
5 AM Ventures5 AM Ventures, Atlas Venture, OrbiMed, Qiming Venture Partners USA / Atlas Venture, OrbiMed / 5AM Ventures, Atlas Venture, OrbiMed and Qiming Ventures
私有 自建(M) ? — —
167 Think Bioscience 美国 US / Colorado — — — 1 轮 2026-01-21 Series A $55M 55
Regeneron VenturesRegeneron Ventures, Innovation Endeavors, Janus Henderson Investors, T.A. Springer, CE-Ventures, MBX Capital, YK Bioventures, AV8 Ventures, CU Innovations and Buff Gold Ventures
私有 自建(H) ? — —
168 SciNeuro Pharmaceuticals 美国 USA / Rockville, MD Multiple CNS disorders Phase 1 1 轮 2025-12-04 未披露轮 $53M 53
LAVArch Venture Partners, LAV / Arch Venture Partners / LAV, ARCH Venture Partners, plus new and existing investors
私有 混合(M) ? ✓ — —
169 Arnatar Therapeutics 美国 USA / San Diego — — — 1 轮 2025-08-25 Series A $52M 52
Eight Roads and 3E BioventuresEight Roads and 3E Bioventures, along with F-Prime Capital, Zhuhai Huajin Capital, Legend Star, Transfar Capital, New Alliance Capital, Yijing Capital, Gaorong Ventures, Jifeng Ventures and Hongsheng Capital
私有 混合(H) 是 — —
170 Third Arc Bio 美国 US / — — — 1 轮 2026-02-04 A extension $52M 52
additional investors include Life SciencNew investor Andreessen Horowitz (a16z) leads the extension with Omega Funds / additional investors include Life Sciences at Goldman Sachs Alternatives, BVF Partners, funds managed by abrdn, accounts advised by T. Rowe Price Associates, Marshall Wace, Hillhouse Investment, Galapagos, AbbVie Ventures and Alderline Group
私有 虚拟(H) 否 — —
171 Caspian Therapeutics 美国 USA / San Diego Small molecules Metabolic diseases Preclinical 1 轮 2026-09-09 Series A $50M 50
BVF PartnersEli Lilly and Company / BVF Partners, T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of Kura’s leadership team and several other biotech entrepreneurs
私有 虚拟(M) ? — —
172 Khartis Therapeutics 美国 USA / San Diego, CA Small molecules Immune diseases Preclinical 1 轮 2026-08-13 Series B $50M 50
Alexandria Venture InvestmentsForge Life Science Partners / Alexandria Venture Investments
私有 不明(L) ? — —
173 Serif Biomedicines 美国 US / Cambridge MA Cell or gene therapy Multiple Preclinical 1 轮 2026-04-21 未披露轮 $50M 50 Flagship Pioneering 私有 自建(M) ? ✓ — —
174 TRexBio 美国 US / San Francisco Biologics Immune diseases Phase 1 1 轮 2026-01-27 Series B $50M 50
Janus Henderson InvestorsEli Lilly and Company, Polaris Partners / Janus Henderson Investors, Balyasny Asset Management, Affinity Asset Advisors, Alexandria Venture Investments, Avego BioScience Capital, Delos Capital, Eli Lilly, Johnson & Johnson Innovation – JJDC, Pfizer Ventures, Polaris Partners and SV Health Investors
上市 混合(H) ? — —
175 AllRock Bio 美国 USA / Natick MA Small molecules Other Phase 1 1 轮 2025-09-16 Series A $50M 50
Versant VenturesVersant Ventures, Westlake Village BioPartners / Versant Ventures / Versant Ventures and Westlake BioPartners
私有 虚拟(M) 否 ✓ — —
176 Sirius Therapeutics 美国 USA / San Diego, CA Nucleic acids Metabolic diseases Phase 1 1 轮 2025-05-09 Series B $50M 50 OrbiMed IPO申请 虚拟(H) 是 — —
177 Etiome 美国 USA / Cambridge, MA Undisclosed Multiple Preclinical 1 轮 2025-04-24 Series A $50M 50 Flagship Pioneering 私有 自建(M) ? ✓ — —
178 Garuda Therapeutics 美国 USA / Cambridge, MA Cell or gene therapy Other Preclinical 1 轮 2025-03-04 Series A $50M 50
OrbiMedOrbiMed / OrbiMed, Northpond Ventures, Cormorant Asset Management and Kyowa Kirin
私有 自建(M) ? @GarudaTx 47
179 Tr1X 美国 US / San Diego — — — 1 轮 2025-10-14 Series N/A $50M 50 Unnamed existing investors 私有 自建(M) 否 — —
180 OncoC4 美国 US / Rockville MD — — — 1 轮 2025-10-02 Series B $50M 50
GBA FundGBA Fund, HM Capital, 3E Bioventures Capital and Kaitai Capital
私有 混合(M) 是 ✓ — —
181 Prolium Bioscience 美国 US / New York — — — 1 轮 2026-03-03 Series A $50M 50 RTW Investments 私有 虚拟(M) ? ✓ — —
182 PsiThera 美国 US / Watertown MA Undisclosed Immune diseases Preclinical 1 轮 2025-12-10 Series A $48M 48
Samsara BioCapitalSamsara BioCapital, Lightstone Ventures / Samsara BioCapital
私有 自建(H) ? ✓ — —
183 Fathom Therapeutics 美国 USA / New York, NY Small molecules Undisclosed Preclinical 1 轮 2026-04-27 Series A $47M 47
Alexandria Venture InvestmentsSutter Hill Ventures / Alexandria Venture Investments
私有 虚拟(L) ? ✓ — —
184 Lifordi Immunotherapeutics 美国 US / Burlington MA Biologics Immune diseases Phase 1 1 轮 2025-11-18 未披露轮 $42M 42
Sanofi VenturesSanofi Ventures, Arch Venture Partners, Atlas Venture
私有 混合(M) ? — —
185 Solu Therapeutics 美国 USA / Boston, MA Biologics Cancer Preclinical 1 轮 2025-04-05 Series A $41M 41
Alexandria Venture InvestmentsAlexandria Venture Investments, Eli Lilly and Company
私有 自建(M) ? @Solu_Tx 37
186 Alloy Therapeutics 美国 USA / Waltham MA Drug discovery Multiple Phase 3 1 轮 2026-04-15 Series E $40M 40 Alexandria Venture Investments 私有 自建(H) ? ✓ @AlloyTx 230
187 Affinia Therapeutics 美国 USA / Waltham MA Cell or gene therapy Other Preclinical 1 轮 2025-10-07 Series C $40M 40
NEANEA / NEA, Atlas Venture, Alexandria Venture Investments, GV, Eli Lilly and Company
私有 自建(M) ? @AffiniaTx 0
188 Therini Bio 美国 USA / South San Francisco, CA Biologics Multiple Phase 1 1 轮 2025-05-14 Series A $39M 39 Eli Lilly and Company, Sanofi Ventures 私有 虚拟(H) 否 — —
189 Vivace Therapeutics 美国 US / San Mateo CA Small molecules Cancer Phase 1 1 轮 2025-03-12 Series D $35M 35 RA Capital Management 私有 虚拟(M) 是 — —
190 Northlinks Bio 美国 US / Boston Small molecules Infectious diseases Phase 2 1 轮 2026-06-23 未披露轮 $34M 34 RA Capital Management 私有 虚拟(H) 否 — —
191 Cloverleaf Bio 美国 USA / New Haven, CT Nucleic acids Cancer Preclinical 1 轮 2026-09-08 Seed $33M 33 4BIO Capital / Eli Lilly and Company 私有 自建(M) ? @cloverleafbio 26
192 Oak Hill Bio 美国 USA / Morristown, NJ Nucleic acids Rare diseases Phase 2 1 轮 2026-06-01 Series A $33M 33
Balyasny Asset ManagementBalyasny Asset Management, venBio, Janus Henderson Investors / venBio
私有 虚拟(H) ? ✓ — —
193 Secretome Therapeutics 美国 USA / Plano, TX Cell or gene therapy Rare diseases Preclinical 1 轮 2026-05-28 Series A $30M 30 RA Capital Management 私有 混合(M) 否 @SecretomeTx 16
194 Grove Biopharma 美国 USA / Chicago, IL Biologics Multiple Preclinical 1 轮 2025-04-23 Series A $30M 30 DCVC Bio / Eli Lilly and Company 私有 自建(H) ? — —
195 Auron Therapeutics 美国 USA / Boston MA Small molecules Cancer Preclinical 1 轮 2025-02-04 Series B $27M 27 DCVC Bio / Polaris Partners 私有 混合(M) 否 ✓ — —
196 AeroRx Therapeutics 美国 USA / La Jolla CA Small molecules Other Phase 2 1 轮 2025-10-07 Series A $21M 21
Alexandria Venture InvestmentsAvalon BioVentures / Alexandria Venture Investments
私有 虚拟(H) ? — —
197 Tavo Biotherapeutics 美国 USA / Laguna Beach, CA Biologics Eye diseases Phase 1 1 轮 2026-06-02 Series A $17M 17 Pureos Bioventures / Polaris Partners 私有 虚拟(M) ? — —
198 Perceive Pharma 美国 US / San Francisco Biologics Other Preclinical 1 轮 2025-02-18 Series A $15M 15 Deerfield Management 私有 不明(L) ? — —
199 Cirrus Therapeutics 美国 USA / Cambridge, MA Cell or gene therapy Eye diseases Preclinical 1 轮 2025-10-02 Seed $11M 11 ClavystBio / Polaris Partners 私有 混合(M) 否 — —
200 Remedium Bio 美国 USA / Needham, MA Cell or gene therapy Multiple Preclinical 1 轮 2026-08-10 Series A $10M 10
Lifespan Vision VenturesLifespan Vision Ventures / Eli Lilly and Company
私有 虚拟(M) 否 — —
201 Be Biopharma 美国 USA / Cambridge MA Cell or gene therapy Other Phase 1 1 轮 2025-01-15 Series C $10M 10
Arch Venture PartnersNextech / Arch Venture Partners, Atlas Venture, RA Capital Management
私有 混合(M) 否 — —
202 Isomorphic Labs 欧洲 UK / London Drug discovery Undisclosed Preclinical
2 轮2025-03-31 未披露轮 $600M
2026-05-12 Series B $2100M
2026-05-12 Series B $2100M 2700
Thrive CapitalThrive Capital / GV / Led by Thrive Capital with participation from Google’s GV and follow-on capital from Alphabet / Thrive Capital, Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund
私有 虚拟(H) ? ✓ @IsomorphicLabs 66k
203 Verdiva Bio 欧洲 UK / London Biologics Metabolic diseases Phase 1 1 轮 2025-01-09 Series A $411M 411
Forbion and General AtlanticForbion, General Atlantic / Forbion, RA Capital Management, OrbiMed / Co-led by Forbion and General Atlantic, with RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures and LYFE Capital
私有 虚拟(M) 是 ✓ — —
204 Windward Bio 欧洲 Switzerland / Basel Biologics Immune diseases Phase 1
2 轮2025-01-10 Series A $200M
2026-05-04 Crossover $165M
2026-05-04 Crossover $165M 365
OrbiMedOrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities / OrbiMed, Novo Holdings / Led by OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities, with SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal bioVenture Partners / OrbiMed / OrbiMed, RA Capital Management, Novo Holdings, Sanofi Ventures
IPO申请 虚拟(H) 是 ✓ — —
205 Tubulis 欧洲 Germany / Munich Biologics Cancer Phase 1 1 轮 2025-10-15 Series C $361M 361
Venrock Healthcare Capital PartnersVenrock Healthcare Capital Partners / EQT Life Sciences / Venrock Healthcare Capital Partners, Wellington Management, Ascenta Capital, Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, High-Tech Gründerfonds (HTGF), OCCIDENT and Seventure Partners
被收购 混合(H) 是 — —
206 CellCentric 欧洲 UK / Cambridge Small molecules Cancer Phase 2
2 轮2025-05-19 Series C $120M
2026-05-06 Series D $220M
2026-05-06 Series D $220M 340
RA Capital ManagementRA Capital, Forbion / RA Capital Management, Forbion, Avego Bioscience Capital, and the American Cancer Society’s venture capital arm / Venrock / Sofinnova Partners, RA Capital Management, Forbion
私有 虚拟(M) 是 @CellCentric 699
207 OMass Therapeutics 欧洲 UK / Oxford Small molecules Multiple Phase 1 1 轮 2026-10-15 Series C $310M 310
Novo HoldingsNovo Holdings, Bain Capital Life Sciences, Forbion / Novo Holdings, Bain Capital Life Sciences, Forbion, GV, Sanofi Ventures
私有 自建(H) ? @omasstx 595
208 Draig Therapeutics 欧洲 UK / Cardiff Small molecules CNS disorders Phase 1
2 轮2025-06-18 Series A $140M
2026-07-14 Series B $65M
2026-07-14 Series B $65M 205
Access BiotechnologyAccess Biotechnology / Sanofi Ventures / Access Biotechnology, Canaan Partners, SR One, Sanofi Ventures, Schroders Capital, SV Health Investors, and ICG / Deep Track Capital, Janus Henderson Investors, Marshall Wace, British Business Bank and Jefferson Life Sciences
私有 虚拟(M) ? — —
209 Bionyra 欧洲 France / Paris Biologics Immune diseases Phase 1 1 轮 2026-06-22 Series A $165M 165
Sofinnova PartnersJeito Capital, Sofinnova Partners / Sofinnova Partners, Sanofi Ventures
私有 虚拟(M) 是 ✓ — —
210 Hemab Therapeutics 欧洲 Denmark / Copenhagen Biologics Rare diseases Phase 2 1 轮 2025-10-27 Series C $157M 157
Sofinnova PartnersSofinnova Partners / Sofinnova Partners, RA Capital Management, Novo Holdings / Sofinnova Partners, Avoro Capital Advisors, RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro Ventures, Maj Invest Equity, Rock Springs Capital and an unnamed global asset management company
上市 混合(M) 是 @Hemab_Tx 200
211 Vaderis Therapeutics 欧洲 Switzerland / Basel Small molecules Rare diseases Phase 3 1 轮 2026-08-11 Series B $152M 152
Life Sciences at Goldman Sachs AlternatiLife Sciences at Goldman Sachs Alternatives, TCGX / EQT Life Sciences / Life Sciences at Goldman Sachs Alternatives, TCGX, Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, Medicxi and Droia
私有 虚拟(M) ? — —
212 Azafaros 欧洲 Netherlands / Leiden Small molecules Rare diseases Phase 2 1 轮 2025-05-13 Series B $147M 147
Jeito CapitalJeito Capital, Forbion / Forbion / Jeito Capital, Forbion Growth, Seroba, Pictet Group, Forbion Ventures, Schroders Capital and BioGeneration Ventures
私有 虚拟(M) ? — —
213 AAVantgarde 欧洲 Italy / Milan Cell or gene therapy Eye diseases Phase 1 1 轮 2025-11-03 Series B $141M 141
Schroders CapitalSchroders Capital, Atlas Venture, Forbion / Atlas Venture, Forbion / Schroders Capital, Atlas Venture, Forbion, Amgen Ventures, Athos Capital, CDP Venture Capital through its Large Ventures Fund, Columbia IMC, Neva SGR, Sixty Degree Capital, XGen Venture, Willett Advisors, Longwood Fund and Sofinnova Partners
私有 混合(M) 否 — —
214 Basecamp Research 欧洲 UK / London — — — 1 轮 2026-09-23 Series C $140M 140
S32S32, Anthropic's Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures
私有 自建(M) 否 ✓ @Basecamp_Res 1.9k
215 Nouscom 欧洲 Switzerland / Basel Vaccines Infectious diseases Phase 1 1 轮 2026-10-19 Series D $135M 135
EQT Life SciencesM Ventures, Revelation Partners / EQT Life Sciences, Versant Ventures
私有 混合(M) 否 — —
216 SpliceBio 欧洲 Spain / Barcelona Cell or gene therapy Eye diseases Phase 1 1 轮 2025-06-11 Series B $135M 135
EQT Life SciencesEQT Life Sciences, Sanofi Ventures / EQT Life Sciences, NEA, Sanofi Ventures / EQT Life Sciences, Sanofi Ventures, Roche Venture Fund, New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund and Asabys Partners
私有 自建(M) ? @SpliceBioHQ 325
217 Artbio 欧洲 Norway / Oslo Radiopharmaceuticals Cancer Phase 0 1 轮 2025-07-29 Series B $132M 132
Sofinnova InvestmentsSofinnova Investments, B Capital / Sofinnova Investments, F-Prime Capital, Third Rock Ventures, Alexandria Venture Investments / Sofinnova Investments, B Capital and a life sciences fund that invested previously, along with existing investors F-Prime, Omega Funds and Third Rock Ventures and new investors Qatar Investment Authority and Alexandria Venture Investments
私有 混合(M) 否 — —
218 GlycoEra 欧洲 Switzerland / Schlieren (Zurich) Biologics Immune diseases Preclinical 1 轮 2025-05-27 Series B $130M 130
Sofinnova PartnersNovo Holdings / Sofinnova Partners, Novo Holdings
私有 自建(M) ? — —
219 Coultreon Biopharma 欧洲 Belgium / Leuven Small molecules Immune diseases Phase 1 1 轮 2026-04-28 Series A $125M 125
Sofinnova InvestmentsSofinnova Investments, Forbion, Novo Holdings / Sofinnova Investments, Forbion, Novo Holdings, Samsara BioCapital / Sofinnova Investments, Forbion, Novo Holdings, Galapagos, Regeneron Ventures, Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund and Finchley Healthcare Ventures
私有 虚拟(L) ? ✓ — —
220 Adcytherix 欧洲 France / Paris Biologics Cancer Preclinical 1 轮 2025-10-16 Series A $122M 122
BpifranceBpifrance, Kurma Partners, Andera Partners, Angelini Ventures / RA Capital Management / Bpifrance, Kurma Partners, Andera Partners, Angelini Ventures, Citadel's Surveyor Capital, aMoon and existing investors
私有 虚拟(M) 是 — —
221 RQ Bio 欧洲 UK / London Biologics Infectious diseases Preclinical 1 轮 2026-06-24 Series A $115M 115
Frazier Life SciencesFrazier Life Sciences / EQT Life Sciences, Forbion / Frazier Life Sciences, EQT Life Sciences, Forbion, Monograph, Wellington Management, LifeArc Ventures, Oxford Science Enterprises and the University of Oxford
私有 混合(M) 否 — —
222 Artios Pharma 欧洲 UK / Cambridge Biologics Cancer Phase 2 1 轮 2025-11-17 Series D $115M 115
SV Health InvestorsSV Health Investors, RA Capital Management / RA Capital Management, Sofinnova Partners, EQT Life Sciences / SV Health Investors, RA Capital Management, Janus Henderson Investors and unnamed existing investors
私有 混合(M) ? @artiospharma 796
223 Granite Bio 欧洲 Switzerland / Basel — — — 1 轮 2025-04-24 A & B $100M 100
Versant VenturesVersant Ventures, Novartis Venture Fund, Forbion and Sanofi Ventures
私有 虚拟(M) ? — —
224 Nuclidium 欧洲 Switzerland / Basel — — — 1 轮 2025-07-10 Series B $99M 99
Kurma Growth Opportunities FundKurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, Neva SGR (Intesa Sanpaolo Group), DeepTech & Climate Fonds, Bayern Kapital, Eurazeo, Vives Partners, NRW.BANK, HighLight Capital, plus other unnamed existing investors
私有 虚拟(M) 否 — —
225 NanoPhoria Biosciences 欧洲 Italy / Milan Biologics Other Preclinical 1 轮 2025-10-06 Series A $97M 97
XGEN VentureXGEN Venture, Sofinnova Partners, CDP Venture Capital / Sofinnova Partners
私有 虚拟(M) ? — —
226 Trogenix 欧洲 UK / Glasgow Cell or gene therapy Cancer Preclinical 1 轮 2025-10-06 Series A $95M 95 IQ Capital / Eli Lilly and Company 私有 虚拟(L) ? — —
227 Orbis Medicines 欧洲 Denmark / Copenhagen Biologics Undisclosed Preclinical 1 轮 2025-01-06 Series A $93M 93
NEA (New Enterprise Associates)NEA / Forbion, NEA, Eli Lilly and Company, Novo Holdings / NEA (New Enterprise Associates), Eli Lilly, Cormorant, the Export and Investment Fund of Denmark, and founding investors Novo Holdings and Forbion
私有 自建(H) ? ✓ — —
228 AnaCardio 欧洲 Sweden / Stockholm Small molecules Other Phase 1
2 轮2025-01-09 Series A $19M
2026-09-30 Series B $71M
2026-09-30 Series B $71M 90
Novo HoldingsNovo Holdings, Pureos Bioventures, Sound Bioventures / Novo Holdings / Novo Holdings, Ljungström family office / Novo Holdings, the Ljungström family office, Helsinn, Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, LLD Nybohov Invest AB and Innovestor Life Science
私有 虚拟(H) ? ✓ — —
229 Immutrin 欧洲 UK / Cambridge/London Biologics Rare diseases Preclinical 1 轮 2026-03-24 Series A $87M 87
Frazier Life SciencesFrazier Life Sciences / F-Prime Capital / Frazier Life Sciences, F-Prime, Qiming Venture Partners, SR One, Cambridge Innovation Capital and Cambridge Enterprise Ventures
私有 自建(M) ? — —
230 Ona Therapeutics 欧洲 Spain / Barcelona — — — 1 轮 2026-06-04 Series B $87M 87
Columbus Venture PartnersColumbus Venture Partners, Mérieux Equity Partners, COFIDES, Korys, Alta Life Sciences, Asabys Partners, Bpifrance, CDTI, FundPlus NV and Ysios Capital
私有 混合(M) 是 @OnaTherapeutics 401
231 Augustine Therapeutics 欧洲 Belgium / Leuven Small molecules CNS disorders Preclinical 1 轮 2025-03-24 Series A $85M 85
Jeito CapitalNovo Holdings, Jeito Capital / Eli Lilly and Company, Novo Holdings / Jeito Capital, Novo Holdings, Asabys Partners, Eli Lilly, AdBio Partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, Charcot-Marie-Tooth Research Foundation and Newton Biocapital
私有 混合(M) ? ✓ — —
232 Cytospire Therapeutics 欧洲 UK / London — — — 1 轮 2026-05-05 Series A $83M 83
4BIO Capital4BIO Capital, Servier Ventures, British Business Bank, Sound Bioventures, Criteria Bio Ventures, Abingworth, LifeArc Ventures, Modi Ventures, Medical Incubator Japan and Pathway Bioventures
私有 自建(M) ? — —
233 Charm Therapeutics 欧洲 UK / London Small molecules Cancer Preclinical 1 轮 2025-09-02 Series B $80M 80
New Enterprise AssociatesNEA, SR One / OrbiMed, F-Prime Capital / New Enterprise Associates, SR One, OrbiMed, F-Prime, Khosla Ventures and NVIDIA
私有 自建(M) ? ✓ — —
234 Mosanna Therapeutics 欧洲 Switzerland / Basel Small molecules Other Phase 1 1 轮 2025-06-09 Series A $80M 80
Pivotal bioVenture PartnersPivotal bioVenture Partners, EQT Life Sciences / EQT Life Sciences, Forbion / Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Broadview Ventures, Norwest, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds
私有 虚拟(M) ? — —
235 Breye 欧洲 Denmark / Copenhagen Small molecules Eye diseases Phase 1 1 轮 2026-09-29 Series A $77M 77
Mission BioCapitalMission BioCapital, Novo Holdings / Novo Holdings / Mission BioCapital, Novo Holdings, Sound Bioventures, Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures and Pappas Capital
私有 虚拟(M) ? ✓ — —
236 Actithera 欧洲 Norway / Oslo Radiopharmaceuticals Cancer Preclinical 1 轮 2025-07-09 Series A $76M 76
M VenturesM Ventures, Hadean Ventures, Sofinnova Partners, 4BIO Capital / Sofinnova Partners / M Ventures, Hadean Ventures, Sofinnova Partners, 4BIO Capital, Bioqube Ventures, Innovestor's Life Science Fund, Investinor, Surveyor Capital and Arkin Bio Ventures II
私有 自建(M) ? — —
237 Juvenescence 欧洲 UK / London — — — 1 轮 2025-05-21 Series B-1 $76M 76
Abu Dhabi’s M42 with “follow-on investmeAbu Dhabi’s M42 with “follow-on investments from existing investors.”
私有 虚拟(M) ? ✓ — —
238 Adcendo 欧洲 Denmark / Copenhagen Biologics Cancer Phase 1 1 轮 2026-04-14 Series C $75M 75
RA Capital ManagementJeito Capital / RA Capital Management, OrbiMed, Novo Holdings
私有 虚拟(M) 是 ✓ — —
239 Beacon Therapeutics 欧洲 UK / London — — — 1 轮 2026-01-08 Series C $75M 75
Life Sciences at Goldman Sachs AlternatiLife Sciences at Goldman Sachs Alternatives, the Retinal Degeneration Fund, the venture arm of Foundation Fighting Blindness, Syncona Limited, Forbion, Oxford Science Enterprises and Advent Life Sciences
私有 虚拟(M) 否 @BeaconTx_ 1.9k
240 Maxion Therapeutics 欧洲 UK / Cambridge Biologics Immune diseases Preclinical 1 轮 2025-03-17 Series A $72M 72
General CatalystGeneral Catalyst / Eli Lilly and Company / Led by General Catalyst, with British Patient Capital, Solasta Ventures, Eli Lilly and Company, LifeArc Ventures, Monograph Capital and BGF
私有 自建(H) ? — —
241 Elevara Medicines 欧洲 UK / London Small molecules Immune diseases Phase 1
2 轮2025-10-21 Series A $70M
2025-10-22 Series A $70M
2025-10-22 Series A $70M 70
ForbionForbion, Sofinnova Partners, Weatherden and Monograph Capital / Forbion, Sofinnova Partners
私有 虚拟(M) ? ✓ — —
242 Leyden Labs 欧洲 Netherlands / Leiden Biologics Infectious diseases Phase 1 1 轮 2025-01-09 未披露轮 $70M 70
ClavystBio and Polaris PartnersClavystBio, Polaris Partners / Polaris Partners, GV / Co-led by ClavystBio and Polaris Partners, with Qiming Venture Partners and existing investors
私有 自建(M) ? @LeydenLabs 139
243 NRG Therapeutics 欧洲 UK / Stevenage — — — 1 轮 2025-09-08 Series B $67M 67
SV Health Investors’ Dementia DiscoverySV Health Investors’ Dementia Discovery Fund, British Business Bank, M Ventures, Novartis Venture Fund, Criteria Bio Ventures, Omega Funds, Brandon Capital and Parkinson’s UK
私有 混合(M) 否 @NrgTherapeutics 76
244 Alesta Therapeutics 欧洲 Netherlands / Leiden — — — 1 轮 2025-01-08 Series A $67M 67
Frazier Life Sciences and Droia VenturesCo-led by Frazier Life Sciences and Droia Ventures, with participation from Novartis Venture Fund, RTW Investments, RV Invest, Thuja Capital and SSI Strategy
被收购 虚拟(M) ? ✓ — —
245 Oncomatryx 欧洲 Spain / Derio (Basque Country) — — — 1 轮 2026-03-30 Series B $67M 67
The Spanish government through Centro paThe Spanish government through Centro para el Desarrollo Tecnologico e Innovacion, Kutxa Fundazioa, the Basque Government, Ekarpen VC, BBK and others
私有 混合(L) 否 ✓ @Oncomatryx 181
246 Haya Therapeutics 欧洲 Switzerland / Lausanne Nucleic acids Multiple Preclinical 1 轮 2025-05-08 Series A $65M 65
Sofinnova PartnersSofinnova Partners / Sofinnova Partners, Alexandria Venture Investments, Eli Lilly and Company / Sofinnova Partners, Earlybird Venture Capital, Eli Lilly and Company, ATHOS, +ND Capital, Alexandria Venture Investments, LifeLink Ventures, Apollo Health Ventures, Longview Ventures, 4see ventures, BERNINA Bioinvest and Schroders Capital
私有 自建(H) ? @HAYA_lncRNA 617
247 ReproNovo 欧洲 Switzerland / Geneva — — — 1 轮 2025-05-21 Series A $65M 65
Jeito CapitalJeito Capital, AXA IM Alts,  M Ventures, Ysios Capital and ALSA Ventures
私有 虚拟(M) 否 ✓ — —
248 MRM Health 欧洲 Belgium / Ghent — — — 1 轮 2025-09-04 Series B $64M 64
BiocodexBiocodex, ATHOS, BNP Paribas Fortis Private Equity, SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB
私有 混合(H) 否 ✓ — —
249 Exciva 欧洲 Germany / Heidelberg Small molecules CNS disorders Phase 1 1 轮 2026-01-20 Series B $59M 59
GimvEQT Life Sciences, Gimv / EQT Life Sciences / Gimv, EQT Life Sciences, Fountain Healthcare Partners, LifeArc Ventures, Carma Fund, Modi Ventures, Andera Partners and LBBW
私有 虚拟(H) ? — —
250 Storm Therapeutics 欧洲 UK / Cambridge — — — 1 轮 2026-04-16 Series C $56M 56
M VenturesM Ventures, Pfizer Ventures, Taiho Ventures, IP Group, the UTokyo Innovation Platform and Fast Track Initiative
私有 混合(H) ? @storm_tx 970
251 Numab Therapeutics 欧洲 Switzerland / Wadenswil Biologics Multiple Phase 1
2 轮2025-01-09 Series C $55M
2025-01-10 C extension $55M
2025-01-10 C extension $55M 55
Cormorant Asset ManagementCormorant Asset Management, Forbion, HBM Healthcare Investment, Novo Holdings / Forbion, Novo Holdings / Cormorant Asset Management, Forbion Growth Opportunities Fund, HBM Healthcare Investment, Novo Holdings, BVF Partners, Octagon Capital Advisors, RTW Investments, and funds and accounts managed by BlackRock
私有 自建(M) ? @Numab_Tx 140
252 Avidicure 欧洲 Netherlands / Leiden Biologics Cancer Preclinical 1 轮 2025-04-24 Seed $50M 50 EQT Life Sciences 私有 自建(M) ? — —
253 Kynexis 欧洲 Netherlands / Naarden Small molecules CNS disorders Phase 2 1 轮 2026-08-19 Series A $47M 47 Novartis Venture Fund / Forbion 私有 虚拟(M) ? ✓ — —
254 Mironid 欧洲 UK / Glasgow Small molecules Other Preclinical 1 轮 2026-08-05 Series B $46M 46 Sofinnova Partners 私有 虚拟(M) ? — —
255 Mestag Therapeutics 欧洲 UK / Cambridge Biologics Cancer Preclinical 1 轮 2026-03-17 未披露轮 $40M 40 GV, Forbion 私有 自建(H) ? @Mestagtx 142
256 Aerska 欧洲 Ireland / Dublin Nucleic acids CNS disorders Preclinical 1 轮 2026-02-09 Series A $39M 39 EQT Life Sciences 私有 混合(M) ? — —
257 Coave Therapeutics 欧洲 France / Paris Cell or gene therapy CNS disorders Preclinical 1 轮 2025-01-09 Series A $33M 33 Novo Holdings, Bpifrance / Novo Holdings 私有 混合(M) 否 — —
258 T-Therapeutics 欧洲 UK / Cambridge Biologics Multiple Preclinical 1 轮 2025-11-13 Series A $32M 32 Sofinnova Partners, Sanofi Ventures 私有 自建(M) ? — —
259 Alchemab Therapeutics 欧洲 UK / London Biologics Other Preclinical 1 轮 2025-09-09 Series A $32M 32 Eli Lilly and Company, RA Capital 私有 自建(H) ? ✓ @alchemabtx 389
260 Tribune Therapeutics 欧洲 Sweden / Stockholm Biologics Other Preclinical 1 轮 2025-03-26 Series A $25M 25 LifeArc Ventures / Novo Holdings 私有 自建(L) ? — —
261 DISCO Pharmaceuticals 欧洲 Germany / Cologne Biologics Cancer Preclinical 1 轮 2025-12-11 Seed $19M 19
Ackerman & van HaarenAckerman & van Haaren, NRW.Bank / Sofinnova Partners
私有 自建(H) ? — —
262 Signadori Bio 欧洲 France / Paris Cell or gene therapy Cancer Preclinical 1 轮 2026-05-06 Seed $13M 13 Taiho Capital / Sofinnova Partners 私有 虚拟(M) 否 — —

本页数字与下一篇《自建、混合还是虚拟》一致;逐家证据与来源见该篇第二部分。

本文为个人研究笔记,结论基于成文时可获得的公开信息;带〔估算〕〔推断〕或⚠️的数字未经独立核实。